FantasyX personal page - To The Moon

FantasyX

FantasyX

No personal profile

117Follow

2Followers

0Topic

0Badge

2022-10-26

2021-08-30

Ho

August jobs report, Consumer confidence: What to know this week

2021-08-27

Mive

Wall Street loses ground, snapping rally on Afghanistan, Fed concerns

2021-08-26

Hi

Sorry, the original content has been removed

2021-08-25

Hi

Sorry, the original content has been removed

2021-08-24

Hi

What Jackson Hole Could Mean For Apple Stock

2021-08-18

Hi

Sorry, the original content has been removed

2021-08-17

Hi

Sorry, the original content has been removed

2021-08-16

Nice

Sorry, the original content has been removed

2021-08-15

Ok

Sorry, the original content has been removed

2021-08-13

Hi

Sorry, the original content has been removed

2021-08-11

Hi

Sorry, the original content has been removed

2021-08-10

Hi

Here's Who's Making a $1 Billion Bet on Moderna

2021-08-09

Nice

BioNTech says has supplied more than 1 bln COVID-19 vaccine doses so far

2021-08-09

Nice

Crypto sector stocks rose in premarket trading,BTCM shares jumped more than 30%,BITF surged more than 20%.

2021-08-05

Hi

Stocks open slightly higher after fall in jobless claims

2021-08-04

Wow

Sorry, the original content has been removed

2021-08-03

Woe

Sorry, the original content has been removed

2021-08-03

Hi

Sorry, the original content has been removed

2021-08-02

Hi

Can Last Year's Biggest Vaccine Stocks Crush the Market Again?

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3581492791156392","uuid":"3581492791156392","gmtCreate":1618399598199,"gmtModify":1626584756234,"name":"FantasyX","pinyin":"fantasyx","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":117,"tweetSize":34,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.10","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9988518494,"gmtCreate":1666785905818,"gmtModify":1676537805898,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$</a>","listText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$</a>","text":"$Apple(AAPL)$","images":[{"img":"https://community-static.tradeup.com/news/198fd190c92da4f742ff2edfab7f7cfc","width":"1080","height":"1782"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9988518494","isVote":1,"tweetType":1,"viewCount":203,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":811806284,"gmtCreate":1630304774548,"gmtModify":1676530262622,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Ho","listText":"Ho","text":"Ho","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/811806284","repostId":"2163776380","repostType":4,"repost":{"id":"2163776380","kind":"news","pubTimestamp":1630268536,"share":"https://ttm.financial/m/news/2163776380?lang=&edition=fundamental","pubTime":"2021-08-30 04:22","market":"other","language":"en","title":"August jobs report, Consumer confidence: What to know this week","url":"https://stock-news.laohu8.com/highlight/detail?id=2163776380","media":"Yahoo Finance","summary":"New data on the U.S. labor market will be in focus this week, offering an updated look at how economic activity has been impacted as the spread of the Delta variant ramped up in the U.S. over the summer.The Labor Department's August jobs report will be the marquee economic report out this week. Consensus economists expect to see that a still-robust 750,000 jobs came back in August, according to Bloomberg data. This would represent a significant print by pre-pandemic standards, but still mark a d","content":"<p>New data on the U.S. labor market will be in focus this week, offering an updated look at how economic activity has been impacted as the spread of the Delta variant ramped up in the U.S. over the summer.</p>\n<p>The Labor Department's August jobs report will be the marquee economic report out this week. Consensus economists expect to see that a still-robust 750,000 jobs came back in August, according to Bloomberg data. This would represent a significant print by pre-pandemic standards, but still mark a deceleration from July's increase of 943,000 jobs. The unemployment rate likely improved further, reaching 5.2% from the 5.4% reported during July.</p>\n<p>The August jobs report is set to be an especially telling report, capturing the impact of the latest surge in coronavirus cases on the U.S. labor market. Other recent economic reports already began to reflect the Delta variant impacts on activity: Job creation in the U.S. services sector slowed by the most since February, while manufacturing sector workforce numbers increased by the least since last year, according to IHS <a href=\"https://laohu8.com/S/MRKT\">Markit</a>'s latest purchasing managers' index reports.</p>\n<p>\"High frequency labor market data are signaling a marked slowdown in employment activity in the August payroll survey week, suggesting downside risk to our forecast,\" Bank of America economist Michelle Meyer wrote in a note on Friday, adding that she expects non-farm payrolls to grow by just 600,000 for August.</p>\n<p>\"Our below-consensus non-farm payrolls forecast is predicated on the markedly weaker high frequency employment data between the July and August payroll survey periods,\" Meyer added. \"Specifically, the Homebase and UKG employment series were both down 3.4% and 2.4%, respectively, over the month.\"</p>\n<p>The outcome of the August jobs report will also be another closely watched data point informing the Federal Reserve's next moves on monetary policy, signaling whether the labor market has recovered enough to warrant a less accommodative tilt. Namely, many Fed officials have been waiting to see the evolution of the labor market recovery to determine the timing for the central bank to announce tapering of its $120 billion per month asset purchase program.</p>\n<p>Last week, Federal Reserve Chair Jerome Powell said during the central bank's virtual Jackson Hole symposium that there has \"been clear progress toward maximum employment\" and suggested \"it could be appropriate to start reducing the pace of asset purchases this year\" if the recovery continues to improve.</p>\n<p>However, he also flagged the ongoing risks introduced by the Delta variant, and added that an \"ill-time policy move\" could knock the recovery off its trajectory.</p>\n<p><img src=\"https://static.tigerbbs.com/67ac641337acd82a0408b6109dad21f9\" tg-width=\"5505\" tg-height=\"3655\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\">NEW YORK, NEW YORK - MAY 27: People walk near Little Island park on May 27, 2021 in New York City. On May 19, all pandemic restrictions, including mask mandates, social distancing guidelines, venue capacities and restaurant curfews were lifted by New York Governor Andrew Cuomo. (Photo by Noam Galai/Getty Images)Noam Galai via Getty Images</p>\n<p>\"Given the emphasis that Powell and other FOMC members have placed on incoming data — especially on the labor market — the payrolls report will probably take on even greater importance than usual,\" Jonas Goltermann, senior markets economist for Capital Economics, wrote in a note on Friday. \"We expect another robust increase in U.S. employment,\"</p>\n<p>Other data in Friday's jobs report will include average hourly wage changes. These are expected to grow 0.3% over last month and 4.0% over last year, with these paces remaining roughly unchanged compared to July. The increases are set to come as job growth slows across lower-wage roles after an initial reopening surge in hiring in the spring and early summer, and as worker shortages push up compensation costs across many firms.</p>\n<h3>Consumer confidence</h3>\n<p>Other economic data due for release this week will reflect consumers' assessments of the recovery.</p>\n<p>The Conference Board's consumer confidence index is set for release on Tuesday, with a drop baked into the forecast. Consensus economists expect the index to slip to 123.0 for August, down from 129.1 in July, according to Bloomberg data. July's print had been the highest since February 2020, marking a rebound in confidence back to pre-pandemic levels.</p>\n<p>The Conference Board's labor differential, or difference between those who said jobs are \"plentiful\" less those who said jobs were \"hard to get,\" also increased to the most since 2000 in last month's report, pointing to the abundance of job openings as employers seek out workers to meet rising demand.</p>\n<p>Consumer confidence and sentiment indices have been monitored closely this year as a gauge of the outlook among Americans at large, pointing to consumers' propensity to spend and presaging demand trends for goods, services and labor down the line. The data have been bumpy in recent months, however, and have ebbed and flowed largely in line with COVID-19 infection trends.</p>\n<p>The latest surge in the Delta variant catalyzed a collapse in the University of Michigan's Surveys of Consumers index for August, suggesting the Conference Board's measure might also see a similar dip for the month. The University of Michigan's consumer sentiment index slid to a 10-year low in August, plunging to 70.3 from July's 81.2.</p>\n<p>\"Consumers' extreme reactions were due to the surging Delta variant, higher inflation, slower wage growth, and smaller declines in unemployment,\" Richard Curtin, Surveys of Consumers chief economist, wrote in a press statement. \"The extraordinary falloff in sentiment also reflects an emotional response, from dashed hopes that the pandemic would soon end and lives could return to normal.\"</p>\n<h3>Economic calendar</h3>\n<ul>\n <li><p><b>Monday: </b>Pending home sales, month-over-month, July (0.4% expected, -1.9% in June); Dallas Fed Manufacturing Activity index, August (23.0 expected, 27.3 in July)</p></li>\n <li><p><b>Tuesday: </b>FHFA Home Price index, month-over-month, June (1.9% expected, 1.7% in May); S&amp;P <a href=\"https://laohu8.com/S/CLGX\">CoreLogic</a> Case-Shiller 20-City index, month-over-month, June (1.87% expected, 1.81% in May); S&amp;P CoreLogic Case-Shiller 20-City index, year-over-year, June (18.60% expected, 16.99% in May); MNI Chicago PMI, August (68.0 expected, 73.4 in July); Conference Board Consumer Confidence, August (123.4 expected, 129.1 in July)</p></li>\n <li><p><b>Wednesday: </b>MBA Mortgage Applications, week ended August 27 (1.6% during prior week); ADP employment change, August (650,000 expected, 330,000 in July); Markit U.S. Manufacturing PMI, August final (61.2 expected, 61.2 in prior print); Construction spending, month-over-month (0.2% expected, 0.1% in June); ISM Manufacturing index, August (58.5 expected, 59.5 in July)</p></li>\n <li><p><b>Thursday: </b>Challenger Job Cuts, year-over-year, August (-92.8% in July); Initial jobless claims, week ended August 28 (346,000 expected, 353,000 during prior week); Continuing claims, week ended August 21 (2.862 million during prior week); Unit labor costs, 2Q final (1.0% expected, 1.0% in prior print); Trade balance, July (-$74.1 billion expected, -$75.7 billion in June); Factory orders, July (0.3% expected, 1.5% in June); Durable goods orders, July final (-0.1% in prior print); Non-defense capital goods orders, excluding aircraft, July final (0.0% in prior print); Non-defense capital goods shipments, July final (1.0% in prior print)</p></li>\n <li><p><b>Friday: </b>Change in non-farm payrolls, August (750,000 expected, 943,000 in July); Change in manufacturing payrolls, August (700,000 expected, 703,000 in July); Unemployment rate, August (5.2% expected, 5.4% in July); Average hourly earnings, month-over-month, August (0.3% expected, 0.4% in July); Average hourly earnings, year-over-year, August (3.9% expected, 4.0% in July); Markit U.S. services PMI, August final (55.2 expected, 55.2 in prior print); Markit U.S. composite PMI, August final (55.4 in prior print); ISM Services Index, August (62.0 expected, 64.1 in July)</p></li>\n</ul>\n<h2>Earnings calendar</h2>\n<ul>\n <li><p><b>Monday: </b><a href=\"https://laohu8.com/S/ZM\">Zoom</a> Video Communications (ZM) after market close</p></li>\n <li><p><b>Tuesday: </b>Crowdstrike (CRWD) after market close</p></li>\n <li><p><b>Wednesday: </b>Campbell Soup (CPB) before market open; Okta (OKTA), Chewy (CHWY), C3.ai (AI), Asana (ASAN) after market close</p></li>\n <li><p><b>Thursday: </b>American Eagle Outfitters (AEO) before market open; Broadcom (AVGO), DocuSign (DOCU), MongoDB (MDB) after market close</p></li>\n <li><p><b>Friday:</b><i> </i>No notable reports scheduled for release</p></li>\n</ul>","source":"yahoofinance_au","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>August jobs report, Consumer confidence: What to know this week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAugust jobs report, Consumer confidence: What to know this week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-30 04:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/august-jobs-report-consumer-confidence-what-to-know-this-week-202216254.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>New data on the U.S. labor market will be in focus this week, offering an updated look at how economic activity has been impacted as the spread of the Delta variant ramped up in the U.S. over the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/august-jobs-report-consumer-confidence-what-to-know-this-week-202216254.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/650fad7fca15e203aa26611c0dfb8d62","relate_stocks":{"WMT":"沃尔玛","TGT":"塔吉特","XRT":"零售指数ETF-SPDR标普","SPY.AU":"SPDR® S&P 500® ETF Trust"},"source_url":"https://finance.yahoo.com/news/august-jobs-report-consumer-confidence-what-to-know-this-week-202216254.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2163776380","content_text":"New data on the U.S. labor market will be in focus this week, offering an updated look at how economic activity has been impacted as the spread of the Delta variant ramped up in the U.S. over the summer.\nThe Labor Department's August jobs report will be the marquee economic report out this week. Consensus economists expect to see that a still-robust 750,000 jobs came back in August, according to Bloomberg data. This would represent a significant print by pre-pandemic standards, but still mark a deceleration from July's increase of 943,000 jobs. The unemployment rate likely improved further, reaching 5.2% from the 5.4% reported during July.\nThe August jobs report is set to be an especially telling report, capturing the impact of the latest surge in coronavirus cases on the U.S. labor market. Other recent economic reports already began to reflect the Delta variant impacts on activity: Job creation in the U.S. services sector slowed by the most since February, while manufacturing sector workforce numbers increased by the least since last year, according to IHS Markit's latest purchasing managers' index reports.\n\"High frequency labor market data are signaling a marked slowdown in employment activity in the August payroll survey week, suggesting downside risk to our forecast,\" Bank of America economist Michelle Meyer wrote in a note on Friday, adding that she expects non-farm payrolls to grow by just 600,000 for August.\n\"Our below-consensus non-farm payrolls forecast is predicated on the markedly weaker high frequency employment data between the July and August payroll survey periods,\" Meyer added. \"Specifically, the Homebase and UKG employment series were both down 3.4% and 2.4%, respectively, over the month.\"\nThe outcome of the August jobs report will also be another closely watched data point informing the Federal Reserve's next moves on monetary policy, signaling whether the labor market has recovered enough to warrant a less accommodative tilt. Namely, many Fed officials have been waiting to see the evolution of the labor market recovery to determine the timing for the central bank to announce tapering of its $120 billion per month asset purchase program.\nLast week, Federal Reserve Chair Jerome Powell said during the central bank's virtual Jackson Hole symposium that there has \"been clear progress toward maximum employment\" and suggested \"it could be appropriate to start reducing the pace of asset purchases this year\" if the recovery continues to improve.\nHowever, he also flagged the ongoing risks introduced by the Delta variant, and added that an \"ill-time policy move\" could knock the recovery off its trajectory.\nNEW YORK, NEW YORK - MAY 27: People walk near Little Island park on May 27, 2021 in New York City. On May 19, all pandemic restrictions, including mask mandates, social distancing guidelines, venue capacities and restaurant curfews were lifted by New York Governor Andrew Cuomo. (Photo by Noam Galai/Getty Images)Noam Galai via Getty Images\n\"Given the emphasis that Powell and other FOMC members have placed on incoming data — especially on the labor market — the payrolls report will probably take on even greater importance than usual,\" Jonas Goltermann, senior markets economist for Capital Economics, wrote in a note on Friday. \"We expect another robust increase in U.S. employment,\"\nOther data in Friday's jobs report will include average hourly wage changes. These are expected to grow 0.3% over last month and 4.0% over last year, with these paces remaining roughly unchanged compared to July. The increases are set to come as job growth slows across lower-wage roles after an initial reopening surge in hiring in the spring and early summer, and as worker shortages push up compensation costs across many firms.\nConsumer confidence\nOther economic data due for release this week will reflect consumers' assessments of the recovery.\nThe Conference Board's consumer confidence index is set for release on Tuesday, with a drop baked into the forecast. Consensus economists expect the index to slip to 123.0 for August, down from 129.1 in July, according to Bloomberg data. July's print had been the highest since February 2020, marking a rebound in confidence back to pre-pandemic levels.\nThe Conference Board's labor differential, or difference between those who said jobs are \"plentiful\" less those who said jobs were \"hard to get,\" also increased to the most since 2000 in last month's report, pointing to the abundance of job openings as employers seek out workers to meet rising demand.\nConsumer confidence and sentiment indices have been monitored closely this year as a gauge of the outlook among Americans at large, pointing to consumers' propensity to spend and presaging demand trends for goods, services and labor down the line. The data have been bumpy in recent months, however, and have ebbed and flowed largely in line with COVID-19 infection trends.\nThe latest surge in the Delta variant catalyzed a collapse in the University of Michigan's Surveys of Consumers index for August, suggesting the Conference Board's measure might also see a similar dip for the month. The University of Michigan's consumer sentiment index slid to a 10-year low in August, plunging to 70.3 from July's 81.2.\n\"Consumers' extreme reactions were due to the surging Delta variant, higher inflation, slower wage growth, and smaller declines in unemployment,\" Richard Curtin, Surveys of Consumers chief economist, wrote in a press statement. \"The extraordinary falloff in sentiment also reflects an emotional response, from dashed hopes that the pandemic would soon end and lives could return to normal.\"\nEconomic calendar\n\nMonday: Pending home sales, month-over-month, July (0.4% expected, -1.9% in June); Dallas Fed Manufacturing Activity index, August (23.0 expected, 27.3 in July)\nTuesday: FHFA Home Price index, month-over-month, June (1.9% expected, 1.7% in May); S&P CoreLogic Case-Shiller 20-City index, month-over-month, June (1.87% expected, 1.81% in May); S&P CoreLogic Case-Shiller 20-City index, year-over-year, June (18.60% expected, 16.99% in May); MNI Chicago PMI, August (68.0 expected, 73.4 in July); Conference Board Consumer Confidence, August (123.4 expected, 129.1 in July)\nWednesday: MBA Mortgage Applications, week ended August 27 (1.6% during prior week); ADP employment change, August (650,000 expected, 330,000 in July); Markit U.S. Manufacturing PMI, August final (61.2 expected, 61.2 in prior print); Construction spending, month-over-month (0.2% expected, 0.1% in June); ISM Manufacturing index, August (58.5 expected, 59.5 in July)\nThursday: Challenger Job Cuts, year-over-year, August (-92.8% in July); Initial jobless claims, week ended August 28 (346,000 expected, 353,000 during prior week); Continuing claims, week ended August 21 (2.862 million during prior week); Unit labor costs, 2Q final (1.0% expected, 1.0% in prior print); Trade balance, July (-$74.1 billion expected, -$75.7 billion in June); Factory orders, July (0.3% expected, 1.5% in June); Durable goods orders, July final (-0.1% in prior print); Non-defense capital goods orders, excluding aircraft, July final (0.0% in prior print); Non-defense capital goods shipments, July final (1.0% in prior print)\nFriday: Change in non-farm payrolls, August (750,000 expected, 943,000 in July); Change in manufacturing payrolls, August (700,000 expected, 703,000 in July); Unemployment rate, August (5.2% expected, 5.4% in July); Average hourly earnings, month-over-month, August (0.3% expected, 0.4% in July); Average hourly earnings, year-over-year, August (3.9% expected, 4.0% in July); Markit U.S. services PMI, August final (55.2 expected, 55.2 in prior print); Markit U.S. composite PMI, August final (55.4 in prior print); ISM Services Index, August (62.0 expected, 64.1 in July)\n\nEarnings calendar\n\nMonday: Zoom Video Communications (ZM) after market close\nTuesday: Crowdstrike (CRWD) after market close\nWednesday: Campbell Soup (CPB) before market open; Okta (OKTA), Chewy (CHWY), C3.ai (AI), Asana (ASAN) after market close\nThursday: American Eagle Outfitters (AEO) before market open; Broadcom (AVGO), DocuSign (DOCU), MongoDB (MDB) after market close\nFriday: No notable reports scheduled for release","news_type":1},"isVote":1,"tweetType":1,"viewCount":366,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":819191431,"gmtCreate":1630040786423,"gmtModify":1676530208375,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Mive","listText":"Mive","text":"Mive","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/819191431","repostId":"2162847016","repostType":4,"repost":{"id":"2162847016","kind":"news","pubTimestamp":1630008724,"share":"https://ttm.financial/m/news/2162847016?lang=&edition=fundamental","pubTime":"2021-08-27 04:12","market":"us","language":"en","title":"Wall Street loses ground, snapping rally on Afghanistan, Fed concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2162847016","media":"Reuters","summary":"NEW YORK, Aug 26 (Reuters) - Wall Street closed lower on Thursday, ending a streak of all-time closi","content":"<p>NEW YORK, Aug 26 (Reuters) - Wall Street closed lower on Thursday, ending a streak of all-time closing highs on concerns over developments in Afghanistan, while fears of a potential shift in U.S. Federal Reserve policy prompted a broad but shallow sell-off the day before the Jackson Hole Symposium.</p>\n<p>All three major U.S. stock indexes ended the session in the red, with the S&amp;P and the Nasdaq notching their first down day in six.</p>\n<p>The sell-off firmed after hawkish commentary from Dallas Fed President Robert Kaplan and a blast outside the Kabul airport in Afghanistan helped strengthen the risk-off sentiment.</p>\n<p>Kaplan, who is not currently a voting member of the Federal Open Markets Committee, said he believes the progress of economic recovery warrants tapering of the Fed's asset purchases to commence in October or shortly thereafter.</p>\n<p>Kaplan's remarks followed earlier comments from the St. Louis Fed President James Bullard, who said that the central bank is \"coalescing\" around a plan to begin tapering process.</p>\n<p>\"(Kaplan’s statements) caused a little confusion about the taper timeline, but in my opinion the equity markets are focused on geopolitical issues,\" said Megan Horneman, director of portfolio strategy at Verdence Capital Advisors in Hunt Valley, Maryland. \"There’s a flight to safety during geopolitical tensions.\"</p>\n<p>\"I am surprised the market the market hasn’t fallen more, given the fear that it could take focus away from (U.S. President Joe Biden's) domestic agenda,\" Horneman added.</p>\n<p>The economy grew at a slightly faster pace than originally reported in the second quarter, fully recovering its losses from the most abrupt downturn in U.S. history, according to the Commerce Department. But jobless claims, though still on a downward trajectory, ticked higher last week.</p>\n<p>The data did little to move the needle with respect to expectations that the Fed is unlikely tip its hand regarding the taper timeline when Chairman Jerome Powell unmutes and delivers his speech at Friday's virtual Jackson Hole Symposium.</p>\n<p>\"We’re going to see a lot of market participants analyze every word (Powell) uses, but at the end of the day, they will begin tapering,\" Horneman said. \"I’m more concerned about the speed at which they taper. What are they going to start with? That will give us a clearer indication as whether they’re getting more hawkish.\"</p>\n<p>The Dow Jones Industrial Average fell 192.38 points, or 0.54%, to 35,213.12, the S&amp;P 500 lost 26.19 points, or 0.58%, to 4,470 and the Nasdaq Composite dropped 96.05 points, or 0.64%, to 14,945.81.</p>\n<p>Of the 11 major sectors in the S&amp;P 500, all but real estate ended the session lower, with energy stocks suffering the steepest percentage loss.</p>\n<p>Discount retailers Dollar General Corp and Dollar Tree Inc slid 3.8% and 12.1%, respectively, after warning higher transportation costs will hurt their bottom lines.</p>\n<p>Coty Inc jumped 14.7% after the cosmetics firm said it expects to post full-year sales growth for the first time in three years.</p>\n<p>Salesforce.com Inc hiked its earnings forecast as the shift to a hybrid work model is expected to fuel strong demand. Its shares advanced 2.7%.</p>\n<p>NetApp Inc jumped 4.7% as brokerages raised their price targets in the wake of the cloud computing firm's better-than-expected 2022 earnings outlook.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 2.99-to-1 ratio; on Nasdaq, a 1.83-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 31 new 52-week highs and two new lows; the Nasdaq Composite recorded 82 new highs and 39 new lows.</p>\n<p>Volume on U.S. exchanges was 8.27 billion shares, compared with the 8.96 billion average over the last 20 trading days. (Reporting by Stephen Culp; Additional reporting by Devik Jain in Bengaluru Editing by Marguerita Choy)</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street loses ground, snapping rally on Afghanistan, Fed concerns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street loses ground, snapping rally on Afghanistan, Fed concerns\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-27 04:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/us-stocks-wall-street-loses-201204459.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK, Aug 26 (Reuters) - Wall Street closed lower on Thursday, ending a streak of all-time closing highs on concerns over developments in Afghanistan, while fears of a potential shift in U.S. ...</p>\n\n<a href=\"https://finance.yahoo.com/news/us-stocks-wall-street-loses-201204459.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","OEX":"标普100","IVV":"标普500指数ETF","SDS":"两倍做空标普500ETF","UPRO":"三倍做多标普500ETF",".SPX":"S&P 500 Index","SPXU":"三倍做空标普500ETF","SSO":"两倍做多标普500ETF","COMP":"Compass, Inc.","SH":"标普500反向ETF","OEF":"标普100指数ETF-iShares"},"source_url":"https://finance.yahoo.com/news/us-stocks-wall-street-loses-201204459.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2162847016","content_text":"NEW YORK, Aug 26 (Reuters) - Wall Street closed lower on Thursday, ending a streak of all-time closing highs on concerns over developments in Afghanistan, while fears of a potential shift in U.S. Federal Reserve policy prompted a broad but shallow sell-off the day before the Jackson Hole Symposium.\nAll three major U.S. stock indexes ended the session in the red, with the S&P and the Nasdaq notching their first down day in six.\nThe sell-off firmed after hawkish commentary from Dallas Fed President Robert Kaplan and a blast outside the Kabul airport in Afghanistan helped strengthen the risk-off sentiment.\nKaplan, who is not currently a voting member of the Federal Open Markets Committee, said he believes the progress of economic recovery warrants tapering of the Fed's asset purchases to commence in October or shortly thereafter.\nKaplan's remarks followed earlier comments from the St. Louis Fed President James Bullard, who said that the central bank is \"coalescing\" around a plan to begin tapering process.\n\"(Kaplan’s statements) caused a little confusion about the taper timeline, but in my opinion the equity markets are focused on geopolitical issues,\" said Megan Horneman, director of portfolio strategy at Verdence Capital Advisors in Hunt Valley, Maryland. \"There’s a flight to safety during geopolitical tensions.\"\n\"I am surprised the market the market hasn’t fallen more, given the fear that it could take focus away from (U.S. President Joe Biden's) domestic agenda,\" Horneman added.\nThe economy grew at a slightly faster pace than originally reported in the second quarter, fully recovering its losses from the most abrupt downturn in U.S. history, according to the Commerce Department. But jobless claims, though still on a downward trajectory, ticked higher last week.\nThe data did little to move the needle with respect to expectations that the Fed is unlikely tip its hand regarding the taper timeline when Chairman Jerome Powell unmutes and delivers his speech at Friday's virtual Jackson Hole Symposium.\n\"We’re going to see a lot of market participants analyze every word (Powell) uses, but at the end of the day, they will begin tapering,\" Horneman said. \"I’m more concerned about the speed at which they taper. What are they going to start with? That will give us a clearer indication as whether they’re getting more hawkish.\"\nThe Dow Jones Industrial Average fell 192.38 points, or 0.54%, to 35,213.12, the S&P 500 lost 26.19 points, or 0.58%, to 4,470 and the Nasdaq Composite dropped 96.05 points, or 0.64%, to 14,945.81.\nOf the 11 major sectors in the S&P 500, all but real estate ended the session lower, with energy stocks suffering the steepest percentage loss.\nDiscount retailers Dollar General Corp and Dollar Tree Inc slid 3.8% and 12.1%, respectively, after warning higher transportation costs will hurt their bottom lines.\nCoty Inc jumped 14.7% after the cosmetics firm said it expects to post full-year sales growth for the first time in three years.\nSalesforce.com Inc hiked its earnings forecast as the shift to a hybrid work model is expected to fuel strong demand. Its shares advanced 2.7%.\nNetApp Inc jumped 4.7% as brokerages raised their price targets in the wake of the cloud computing firm's better-than-expected 2022 earnings outlook.\nDeclining issues outnumbered advancing ones on the NYSE by a 2.99-to-1 ratio; on Nasdaq, a 1.83-to-1 ratio favored decliners.\nThe S&P 500 posted 31 new 52-week highs and two new lows; the Nasdaq Composite recorded 82 new highs and 39 new lows.\nVolume on U.S. exchanges was 8.27 billion shares, compared with the 8.96 billion average over the last 20 trading days. (Reporting by Stephen Culp; Additional reporting by Devik Jain in Bengaluru Editing by Marguerita Choy)","news_type":1},"isVote":1,"tweetType":1,"viewCount":298,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":810626892,"gmtCreate":1629973702016,"gmtModify":1676530188636,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/810626892","repostId":"2162060923","repostType":4,"isVote":1,"tweetType":1,"viewCount":196,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":837270728,"gmtCreate":1629897397664,"gmtModify":1676530165389,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/837270728","repostId":"1153815600","repostType":4,"isVote":1,"tweetType":1,"viewCount":460,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":834243983,"gmtCreate":1629809891742,"gmtModify":1676530138006,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/834243983","repostId":"1192610173","repostType":4,"repost":{"id":"1192610173","kind":"news","pubTimestamp":1629809650,"share":"https://ttm.financial/m/news/1192610173?lang=&edition=fundamental","pubTime":"2021-08-24 20:54","market":"us","language":"en","title":"What Jackson Hole Could Mean For Apple Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1192610173","media":"TheStreet","summary":"In late August, the markets could be rocked by monetary policy news coming from Jackson Hole, Wyomin","content":"<p>In late August, the markets could be rocked by monetary policy news coming from Jackson Hole, Wyoming. Here is what Apple stock investors should expect.</p>\n<p>The week of August 23 will likely prove to be an important one in the markets. Starting on Thursday, central bank leaders from around the world will meet virtually to talk about monetary policy during a traditional&nbsp;event&nbsp;often referred to simply as “Jackson Hole”.</p>\n<p>Today, the Apple Maven discusses how the upcoming meeting of central bankers could impact Apple stock’s&nbsp;performance in the last few trading sessions of August.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb09ec199963ac68c7742982748bf7a0\" tg-width=\"1200\" tg-height=\"800\" width=\"100%\" height=\"auto\"><span>Figure 1: Federal Reserve Chair Jerome Powell in a screen display at NYSE.</span></p>\n<p><b>The interest rate risk</b></p>\n<p>There seems to be a consensus that Federal Reserve chairman Jerome Powell will do little to “rock the boat” this week. Easing off on monetary stimulus is widely expected to occur over the next several months, but few seem confident that Mr. Powell will announce a change in policy as early as August.</p>\n<p>Still, the risk that the Fed will start to scale back its asset purchases later this year is real. Analysts will probably dissect Jerome Powell’s keynote speech, on Friday, in search for clues on the exact timing. Comments perceived to be hawkish could send yields higher – the 10-year treasury rate is only 1.3%.</p>\n<p>If recent history can serve as a guide,climbing yields tend to be bad news&nbsp;for growth stocks. Below are the main reasons why this is the case, as previously discussed on this channel:</p>\n<blockquote>\n “First, monetary tightening is a negative for consumption, everything else held constant. Second, a higher discount rate makes Apple’s far-out financial results less valuable in present value terms.”\n</blockquote>\n<p>For instance, the 10-year rate shot up from around 1% to nearly 1.5% in February alone. Probably not a coincidence, AAPL sank 8% that same month, while the value-rich Dow index managed to reach higher.</p>\n<p><b>Brace for possible volatility</b></p>\n<p>Regardless of which way the stock market may head following the Jackson Hole symposium, volatility could rise as August comes to a close. This is the case because speculation, both on the bullish and bearish sides of the argument, tends to increase around important events like this.</p>\n<p>Volatility is both good and bad news for Apple stock. Market jitters can be uncomfortable for many investors, and some might be tempted to sell or trim their positions after a selloff. On the other hand, a possible pullback that is unrelated to the company’s fundamentals could open an opportunity to buy AAPL on weakness.</p>\n<p>This is precisely what happened in mid-June, following an important Federal Reserve meeting that the market perceived as hawkish. Those&nbsp;who bought AAPL at those levels, a move defended by the Apple Maven, saw the value of their investment rise by 14% in a matter of only about 10 weeks.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What Jackson Hole Could Mean For Apple Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat Jackson Hole Could Mean For Apple Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-24 20:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/apple/news/what-jackson-hole-could-mean-for-apple-stock><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In late August, the markets could be rocked by monetary policy news coming from Jackson Hole, Wyoming. Here is what Apple stock investors should expect.\nThe week of August 23 will likely prove to be ...</p>\n\n<a href=\"https://www.thestreet.com/apple/news/what-jackson-hole-could-mean-for-apple-stock\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.thestreet.com/apple/news/what-jackson-hole-could-mean-for-apple-stock","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192610173","content_text":"In late August, the markets could be rocked by monetary policy news coming from Jackson Hole, Wyoming. Here is what Apple stock investors should expect.\nThe week of August 23 will likely prove to be an important one in the markets. Starting on Thursday, central bank leaders from around the world will meet virtually to talk about monetary policy during a traditional event often referred to simply as “Jackson Hole”.\nToday, the Apple Maven discusses how the upcoming meeting of central bankers could impact Apple stock’s performance in the last few trading sessions of August.\nFigure 1: Federal Reserve Chair Jerome Powell in a screen display at NYSE.\nThe interest rate risk\nThere seems to be a consensus that Federal Reserve chairman Jerome Powell will do little to “rock the boat” this week. Easing off on monetary stimulus is widely expected to occur over the next several months, but few seem confident that Mr. Powell will announce a change in policy as early as August.\nStill, the risk that the Fed will start to scale back its asset purchases later this year is real. Analysts will probably dissect Jerome Powell’s keynote speech, on Friday, in search for clues on the exact timing. Comments perceived to be hawkish could send yields higher – the 10-year treasury rate is only 1.3%.\nIf recent history can serve as a guide,climbing yields tend to be bad news for growth stocks. Below are the main reasons why this is the case, as previously discussed on this channel:\n\n “First, monetary tightening is a negative for consumption, everything else held constant. Second, a higher discount rate makes Apple’s far-out financial results less valuable in present value terms.”\n\nFor instance, the 10-year rate shot up from around 1% to nearly 1.5% in February alone. Probably not a coincidence, AAPL sank 8% that same month, while the value-rich Dow index managed to reach higher.\nBrace for possible volatility\nRegardless of which way the stock market may head following the Jackson Hole symposium, volatility could rise as August comes to a close. This is the case because speculation, both on the bullish and bearish sides of the argument, tends to increase around important events like this.\nVolatility is both good and bad news for Apple stock. Market jitters can be uncomfortable for many investors, and some might be tempted to sell or trim their positions after a selloff. On the other hand, a possible pullback that is unrelated to the company’s fundamentals could open an opportunity to buy AAPL on weakness.\nThis is precisely what happened in mid-June, following an important Federal Reserve meeting that the market perceived as hawkish. Those who bought AAPL at those levels, a move defended by the Apple Maven, saw the value of their investment rise by 14% in a matter of only about 10 weeks.","news_type":1},"isVote":1,"tweetType":1,"viewCount":143,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":831106376,"gmtCreate":1629293500295,"gmtModify":1676529993822,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/831106376","repostId":"2160473456","repostType":4,"isVote":1,"tweetType":1,"viewCount":421,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":833385441,"gmtCreate":1629206272683,"gmtModify":1676529965262,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/833385441","repostId":"1156515289","repostType":4,"isVote":1,"tweetType":1,"viewCount":429,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":830574407,"gmtCreate":1629086128209,"gmtModify":1676529925079,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/830574407","repostId":"1145684106","repostType":4,"isVote":1,"tweetType":1,"viewCount":514,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":830326997,"gmtCreate":1629015248819,"gmtModify":1676529911322,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/830326997","repostId":"2159215676","repostType":4,"isVote":1,"tweetType":1,"viewCount":754,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":894703989,"gmtCreate":1628853144941,"gmtModify":1676529875174,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/894703989","repostId":"2159962232","repostType":4,"isVote":1,"tweetType":1,"viewCount":110,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":892256128,"gmtCreate":1628667305864,"gmtModify":1676529814830,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/892256128","repostId":"1187715628","repostType":4,"isVote":1,"tweetType":1,"viewCount":83,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":896420564,"gmtCreate":1628602326258,"gmtModify":1676529793082,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/896420564","repostId":"2158048475","repostType":4,"repost":{"id":"2158048475","kind":"highlight","pubTimestamp":1628600160,"share":"https://ttm.financial/m/news/2158048475?lang=&edition=fundamental","pubTime":"2021-08-10 20:56","market":"us","language":"en","title":"Here's Who's Making a $1 Billion Bet on Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2158048475","media":"Motley Fool","summary":"The total bet size is even higher.","content":"<p>Few stocks are as hot as&nbsp;<b>Moderna</b> (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.</p>\n<p>That kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.</p>\n<p>There's <a href=\"https://laohu8.com/S/AONE.U\">one</a> investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.</p>\n<h2>Investing heavily</h2>\n<p>Moderna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.</p>\n<p>Actually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&amp;D investments going forward.</p>\n<p>In addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.</p>\n<h2>Why buy back shares?</h2>\n<p>Probably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"</p>\n<p>Another reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.</p>\n<p>Moderna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.</p>\n<p>Repurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&amp;D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.</p>\n<p>Moderna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.</p>\n<h2>A good bet?</h2>\n<p>Just because Moderna <i>can</i> spend $1 billion on share repurchases doesn't mean that it <i>should</i> do so. I don't think Moderna should make that $1 billion bet in buying back shares.&nbsp;My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.</p>\n<p>Of course, Moderna could wait to buy back shares only on pullbacks.&nbsp;However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.</p>\n<p>The company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Who's Making a $1 Billion Bet on Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Who's Making a $1 Billion Bet on Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 20:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158048475","content_text":"Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.\nThere's one investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.\nInvesting heavily\nModerna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.\nActually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&D investments going forward.\nIn addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.\nWhy buy back shares?\nProbably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"\nAnother reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.\nModerna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.\nRepurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.\nModerna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.\nA good bet?\nJust because Moderna can spend $1 billion on share repurchases doesn't mean that it should do so. I don't think Moderna should make that $1 billion bet in buying back shares. My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.\nOf course, Moderna could wait to buy back shares only on pullbacks. However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.\nThe company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.","news_type":1},"isVote":1,"tweetType":1,"viewCount":120,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":898522502,"gmtCreate":1628512921606,"gmtModify":1703507316736,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/898522502","repostId":"2158844506","repostType":4,"repost":{"id":"2158844506","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1628508062,"share":"https://ttm.financial/m/news/2158844506?lang=&edition=fundamental","pubTime":"2021-08-09 19:21","market":"us","language":"en","title":"BioNTech says has supplied more than 1 bln COVID-19 vaccine doses so far","url":"https://stock-news.laohu8.com/highlight/detail?id=2158844506","media":"Reuters","summary":"FRANKFURT, Aug 9 (Reuters) - BioNTech and partner Pfizer have supplied more than one billion doses o","content":"<p>FRANKFURT, Aug 9 (Reuters) - BioNTech and partner Pfizer have supplied more than <a href=\"https://laohu8.com/S/AONE.U\">one</a> billion doses of their COVID-19 vaccine as per July 21, a bigger number than delivered by competitor AstraZeneca , the German biotech group said on Monday.</p>\n<p>AstraZeneca said on July 29 that it and its manufacturing partner, India-based Serum Institute, had supplied a billion doses to 170 countries at the time.</p>\n<p>Based on delivery contracts so far, BioNTech said in a statement it expects 15.9 billion euros ($18.7 billion) in revenue accruing to it from the vaccine this year, up from a forecast in May of 12.4 billion euros.</p>\n<p>That includes sales, milestone payments from partners and a share of gross profit in its partners' territories, the company added. ($1 = 0.8509 euros)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech says has supplied more than 1 bln COVID-19 vaccine doses so far</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech says has supplied more than 1 bln COVID-19 vaccine doses so far\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-09 19:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>FRANKFURT, Aug 9 (Reuters) - BioNTech and partner Pfizer have supplied more than <a href=\"https://laohu8.com/S/AONE.U\">one</a> billion doses of their COVID-19 vaccine as per July 21, a bigger number than delivered by competitor AstraZeneca , the German biotech group said on Monday.</p>\n<p>AstraZeneca said on July 29 that it and its manufacturing partner, India-based Serum Institute, had supplied a billion doses to 170 countries at the time.</p>\n<p>Based on delivery contracts so far, BioNTech said in a statement it expects 15.9 billion euros ($18.7 billion) in revenue accruing to it from the vaccine this year, up from a forecast in May of 12.4 billion euros.</p>\n<p>That includes sales, milestone payments from partners and a share of gross profit in its partners' territories, the company added. ($1 = 0.8509 euros)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158844506","content_text":"FRANKFURT, Aug 9 (Reuters) - BioNTech and partner Pfizer have supplied more than one billion doses of their COVID-19 vaccine as per July 21, a bigger number than delivered by competitor AstraZeneca , the German biotech group said on Monday.\nAstraZeneca said on July 29 that it and its manufacturing partner, India-based Serum Institute, had supplied a billion doses to 170 countries at the time.\nBased on delivery contracts so far, BioNTech said in a statement it expects 15.9 billion euros ($18.7 billion) in revenue accruing to it from the vaccine this year, up from a forecast in May of 12.4 billion euros.\nThat includes sales, milestone payments from partners and a share of gross profit in its partners' territories, the company added. ($1 = 0.8509 euros)","news_type":1},"isVote":1,"tweetType":1,"viewCount":243,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":898522282,"gmtCreate":1628512908346,"gmtModify":1703507317392,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/898522282","repostId":"1122651143","repostType":4,"repost":{"id":"1122651143","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628508488,"share":"https://ttm.financial/m/news/1122651143?lang=&edition=fundamental","pubTime":"2021-08-09 19:28","market":"us","language":"en","title":"Crypto sector stocks rose in premarket trading,BTCM shares jumped more than 30%,BITF surged more than 20%.","url":"https://stock-news.laohu8.com/highlight/detail?id=1122651143","media":"Tiger Newspress","summary":"Crypto sector stocks rose in premarket trading,BTCM shares jumped more than 30%,BITF surged more tha","content":"<p>Crypto&nbsp;sector&nbsp;stocks&nbsp;rose&nbsp;in&nbsp;premarket&nbsp;trading,BTCM&nbsp;shares&nbsp;jumped&nbsp;more&nbsp;than&nbsp;30%,BITF&nbsp;surged&nbsp;more&nbsp;than&nbsp;20%.</p>\n<p><img src=\"https://static.tigerbbs.com/9ece56572cf91d8de69991add19a22f4\" tg-width=\"1287\" tg-height=\"619\" referrerpolicy=\"no-referrer\">Investors in stock trading platforms are citing the momentum in cryptocurrencies as being the driving force for the stock price increase. The price of the Bitcoin cryptocurrency is up more than 9% over the past week. And Ethereum is up more than 12% over the past week.</p>\n<p>Late last month, BIT Mining announced it entered into a definitive purchase agreement to buy 2,500 new bitcoin mining machines for a total consideration of approximately US$6.6 million. And when deployed, the company expects the Acquired Machines to increase its theoretical maximum total hash rate capacity by about 165 peta hashes per second (PH/s).</p>\n<p>The acquired machines are expected to be delivered within one week from today. And following delivery, the company plans for them to be shipped to Kazakhstan for deployment.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Crypto sector stocks rose in premarket trading,BTCM shares jumped more than 30%,BITF surged more than 20%.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCrypto sector stocks rose in premarket trading,BTCM shares jumped more than 30%,BITF surged more than 20%.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-09 19:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Crypto&nbsp;sector&nbsp;stocks&nbsp;rose&nbsp;in&nbsp;premarket&nbsp;trading,BTCM&nbsp;shares&nbsp;jumped&nbsp;more&nbsp;than&nbsp;30%,BITF&nbsp;surged&nbsp;more&nbsp;than&nbsp;20%.</p>\n<p><img src=\"https://static.tigerbbs.com/9ece56572cf91d8de69991add19a22f4\" tg-width=\"1287\" tg-height=\"619\" referrerpolicy=\"no-referrer\">Investors in stock trading platforms are citing the momentum in cryptocurrencies as being the driving force for the stock price increase. The price of the Bitcoin cryptocurrency is up more than 9% over the past week. And Ethereum is up more than 12% over the past week.</p>\n<p>Late last month, BIT Mining announced it entered into a definitive purchase agreement to buy 2,500 new bitcoin mining machines for a total consideration of approximately US$6.6 million. And when deployed, the company expects the Acquired Machines to increase its theoretical maximum total hash rate capacity by about 165 peta hashes per second (PH/s).</p>\n<p>The acquired machines are expected to be delivered within one week from today. And following delivery, the company plans for them to be shipped to Kazakhstan for deployment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BITF":"Bitfarms Ltd.","BTCM":"BIT Mining"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122651143","content_text":"Crypto sector stocks rose in premarket trading,BTCM shares jumped more than 30%,BITF surged more than 20%.\nInvestors in stock trading platforms are citing the momentum in cryptocurrencies as being the driving force for the stock price increase. The price of the Bitcoin cryptocurrency is up more than 9% over the past week. And Ethereum is up more than 12% over the past week.\nLate last month, BIT Mining announced it entered into a definitive purchase agreement to buy 2,500 new bitcoin mining machines for a total consideration of approximately US$6.6 million. And when deployed, the company expects the Acquired Machines to increase its theoretical maximum total hash rate capacity by about 165 peta hashes per second (PH/s).\nThe acquired machines are expected to be delivered within one week from today. And following delivery, the company plans for them to be shipped to Kazakhstan for deployment.","news_type":1},"isVote":1,"tweetType":1,"viewCount":225,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":899807224,"gmtCreate":1628172113068,"gmtModify":1703502544208,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/899807224","repostId":"1102705333","repostType":4,"repost":{"id":"1102705333","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628170059,"share":"https://ttm.financial/m/news/1102705333?lang=&edition=fundamental","pubTime":"2021-08-05 21:27","market":"us","language":"en","title":"Stocks open slightly higher after fall in jobless claims","url":"https://stock-news.laohu8.com/highlight/detail?id=1102705333","media":"Tiger Newspress","summary":"(Aug 5) Stocks open slightly higher after fall in jobless claims.\nDow industrials up 94 points, or 0","content":"<p>(Aug 5)&nbsp;Stocks open slightly higher after fall in jobless claims.</p>\n<p>Dow industrials up 94 points, or 0.3%.&nbsp;S&amp;P 500 up 0.3% at 4,414.12.&nbsp;Nasdaq Composite up less than 0.1% at 14,784.61.&nbsp;</p>\n<p>Fastly plunges over&nbsp;23% in morning trading&nbsp;after the company's downside Q3 and full-year guidance due to the widespread outage in June.</p>\n<p><img src=\"https://static.tigerbbs.com/44fbcf9492918a352919cdff1fd27498\" tg-width=\"727\" tg-height=\"497\" width=\"100%\" height=\"auto\"></p>\n<p>The moves in the stocks came after a mostly lower regular session on Wednesday. The Dow dropped more than 300 points, or 0.9%, and closed near its session low. The S&amp;P 500 slipped about 0.5%, while the Nasdaq Composite ticked up 0.1%.</p>\n<p>Weekly initial jobless claims came in at385,000 on Thursday,in-line with expectations. Recent earnings and economic data have been strong overall, but some economists worry economic growth and employment gains will taper from here.</p>\n<p>The jobless claims data was the last reading before the key July jobs report, which will be released on Friday morning. There is a wide range of estimates from economists and what the report will show, and some metrics for employment gains have disappointed despite a high level of reported job openings.</p>\n<p>\"Many factors are likely driving worker shortages; concerns about catching the virus, childcare responsibilities, skills mismatches, and generous unemployment insurance benefits,\" PNC Senior Economist Abbey Omodunbi said in an email. In the second half of the year, \"more competition for workers, particularly in the leisure and hospitality sector, will support acceleration in wage growth, boosting household incomes and consumer spending.\"</p>\n<p>The results of an ADP private payroll survey released Wednesday showed again of 330,000 jobs for July,well short of the consensus estimate of 653,000. The Labor Department's official jobs report, which typically has more impact on investors, will be released on Friday. Economists expect the report will show the U.S. added 845,000 in non-farm payrolls in July, about even with the previous month, according to Dow Jones estimates.</p>\n<p>The10-year Treasury yieldwas holding steady near 1.8% on Thursday. The yield briefly dipping below 1.13% on Wednesday before bouncing back in late morning trading.</p>\n<p>Shares ofRokudropped 6% after the company issued quarterly results.Etsyfell 12% in early trading after the company gave guidance for the current quarter that indicated the pandemic-fueled commerce boommay be coming to an end.</p>\n<p>However, earnings season has been strong overall. Goldman Sachs raised its year-end target for the S&amp;P 500 to 4,700, representing 7% upside, in part due to an improving earnings outlook going.</p>\n<p>During regular trading Wednesday, shares of Robinhoodsurged 50%, continuing a volatile jump after last week's soft initial public offering. Semiconductor stocks were another bright spot, withNvidiaandAdvanced Micro Devicesrising.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks open slightly higher after fall in jobless claims</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks open slightly higher after fall in jobless claims\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-05 21:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Aug 5)&nbsp;Stocks open slightly higher after fall in jobless claims.</p>\n<p>Dow industrials up 94 points, or 0.3%.&nbsp;S&amp;P 500 up 0.3% at 4,414.12.&nbsp;Nasdaq Composite up less than 0.1% at 14,784.61.&nbsp;</p>\n<p>Fastly plunges over&nbsp;23% in morning trading&nbsp;after the company's downside Q3 and full-year guidance due to the widespread outage in June.</p>\n<p><img src=\"https://static.tigerbbs.com/44fbcf9492918a352919cdff1fd27498\" tg-width=\"727\" tg-height=\"497\" width=\"100%\" height=\"auto\"></p>\n<p>The moves in the stocks came after a mostly lower regular session on Wednesday. The Dow dropped more than 300 points, or 0.9%, and closed near its session low. The S&amp;P 500 slipped about 0.5%, while the Nasdaq Composite ticked up 0.1%.</p>\n<p>Weekly initial jobless claims came in at385,000 on Thursday,in-line with expectations. Recent earnings and economic data have been strong overall, but some economists worry economic growth and employment gains will taper from here.</p>\n<p>The jobless claims data was the last reading before the key July jobs report, which will be released on Friday morning. There is a wide range of estimates from economists and what the report will show, and some metrics for employment gains have disappointed despite a high level of reported job openings.</p>\n<p>\"Many factors are likely driving worker shortages; concerns about catching the virus, childcare responsibilities, skills mismatches, and generous unemployment insurance benefits,\" PNC Senior Economist Abbey Omodunbi said in an email. In the second half of the year, \"more competition for workers, particularly in the leisure and hospitality sector, will support acceleration in wage growth, boosting household incomes and consumer spending.\"</p>\n<p>The results of an ADP private payroll survey released Wednesday showed again of 330,000 jobs for July,well short of the consensus estimate of 653,000. The Labor Department's official jobs report, which typically has more impact on investors, will be released on Friday. Economists expect the report will show the U.S. added 845,000 in non-farm payrolls in July, about even with the previous month, according to Dow Jones estimates.</p>\n<p>The10-year Treasury yieldwas holding steady near 1.8% on Thursday. The yield briefly dipping below 1.13% on Wednesday before bouncing back in late morning trading.</p>\n<p>Shares ofRokudropped 6% after the company issued quarterly results.Etsyfell 12% in early trading after the company gave guidance for the current quarter that indicated the pandemic-fueled commerce boommay be coming to an end.</p>\n<p>However, earnings season has been strong overall. Goldman Sachs raised its year-end target for the S&amp;P 500 to 4,700, representing 7% upside, in part due to an improving earnings outlook going.</p>\n<p>During regular trading Wednesday, shares of Robinhoodsurged 50%, continuing a volatile jump after last week's soft initial public offering. Semiconductor stocks were another bright spot, withNvidiaandAdvanced Micro Devicesrising.</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite","SPY":"标普500ETF",".SPX":"S&P 500 Index"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102705333","content_text":"(Aug 5) Stocks open slightly higher after fall in jobless claims.\nDow industrials up 94 points, or 0.3%. S&P 500 up 0.3% at 4,414.12. Nasdaq Composite up less than 0.1% at 14,784.61. \nFastly plunges over 23% in morning trading after the company's downside Q3 and full-year guidance due to the widespread outage in June.\n\nThe moves in the stocks came after a mostly lower regular session on Wednesday. The Dow dropped more than 300 points, or 0.9%, and closed near its session low. The S&P 500 slipped about 0.5%, while the Nasdaq Composite ticked up 0.1%.\nWeekly initial jobless claims came in at385,000 on Thursday,in-line with expectations. Recent earnings and economic data have been strong overall, but some economists worry economic growth and employment gains will taper from here.\nThe jobless claims data was the last reading before the key July jobs report, which will be released on Friday morning. There is a wide range of estimates from economists and what the report will show, and some metrics for employment gains have disappointed despite a high level of reported job openings.\n\"Many factors are likely driving worker shortages; concerns about catching the virus, childcare responsibilities, skills mismatches, and generous unemployment insurance benefits,\" PNC Senior Economist Abbey Omodunbi said in an email. In the second half of the year, \"more competition for workers, particularly in the leisure and hospitality sector, will support acceleration in wage growth, boosting household incomes and consumer spending.\"\nThe results of an ADP private payroll survey released Wednesday showed again of 330,000 jobs for July,well short of the consensus estimate of 653,000. The Labor Department's official jobs report, which typically has more impact on investors, will be released on Friday. Economists expect the report will show the U.S. added 845,000 in non-farm payrolls in July, about even with the previous month, according to Dow Jones estimates.\nThe10-year Treasury yieldwas holding steady near 1.8% on Thursday. The yield briefly dipping below 1.13% on Wednesday before bouncing back in late morning trading.\nShares ofRokudropped 6% after the company issued quarterly results.Etsyfell 12% in early trading after the company gave guidance for the current quarter that indicated the pandemic-fueled commerce boommay be coming to an end.\nHowever, earnings season has been strong overall. Goldman Sachs raised its year-end target for the S&P 500 to 4,700, representing 7% upside, in part due to an improving earnings outlook going.\nDuring regular trading Wednesday, shares of Robinhoodsurged 50%, continuing a volatile jump after last week's soft initial public offering. Semiconductor stocks were another bright spot, withNvidiaandAdvanced Micro Devicesrising.","news_type":1},"isVote":1,"tweetType":1,"viewCount":137,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":890361126,"gmtCreate":1628084077765,"gmtModify":1703500886221,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/890361126","repostId":"2156909108","repostType":4,"isVote":1,"tweetType":1,"viewCount":150,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":807096428,"gmtCreate":1627986787164,"gmtModify":1703499123034,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Woe","listText":"Woe","text":"Woe","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/807096428","repostId":"2156100119","repostType":4,"isVote":1,"tweetType":1,"viewCount":227,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":807098566,"gmtCreate":1627986720255,"gmtModify":1703499121733,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/807098566","repostId":"1158700064","repostType":4,"isVote":1,"tweetType":1,"viewCount":196,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":804038781,"gmtCreate":1627911555543,"gmtModify":1703497711425,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/804038781","repostId":"2156192895","repostType":4,"repost":{"id":"2156192895","kind":"highlight","pubTimestamp":1627909020,"share":"https://ttm.financial/m/news/2156192895?lang=&edition=fundamental","pubTime":"2021-08-02 20:57","market":"us","language":"en","title":"Can Last Year's Biggest Vaccine Stocks Crush the Market Again?","url":"https://stock-news.laohu8.com/highlight/detail?id=2156192895","media":"Motley Fool","summary":"These players delivered triple- and quadruple-digit gains.","content":"<blockquote>\n <b>These players delivered triple- and quadruple-digit gains.</b>\n</blockquote>\n<p><b>Key <a href=\"https://laohu8.com/S/PCOM\">Points</a></b></p>\n<ul>\n <li>Last year, most coronavirus vaccine stocks were high risk.</li>\n <li>Today, there are investment opportunities for aggressive investors and cautious investors.</li>\n</ul>\n<p>Coronavirus vaccine stocks were the biggest investment theme of 2020. Some players soared more than 1,000% as investors bet on their abilities to bring a billion-dollar product to market. That's as the S&amp;P 500 Index rose about 16%.</p>\n<p>Since, two biotech companies --<b>Moderna</b> (NASDAQ:MRNA) and&nbsp;<b><a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a></b> -- actually have commercialized their vaccines. And they are indeed generating billions of dollars in revenue. But what about some of the other vaccine stocks that scored big on the stock market last year? Let's take a look at where they're at with vaccine programs -- and whether they're on track to beat the market in the second half.</p>\n<p><img src=\"https://static.tigerbbs.com/4892523d64861e597e6e75e31fe85713\" tg-width=\"700\" tg-height=\"467\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<p><b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b></p>\n<p>The program:&nbsp;<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>'s U.S. phase 3 trial of its vaccine candidate showed 90.4% overall efficacy. It demonstrated 100% efficacy in moderate and severe disease. The company fell behind in its submissions to regulators as it ramped up its manufacturing network. For instance, it's faced shortages of certain raw materials needed to produce the vaccine candidate. In May, Novavax said it would file for authorization in various locations worldwide -- including the U.S. -- in the third quarter. And Novavax predicts manufacturing will operate at full capacity as of the fourth quarter.</p>\n<p>The share price: The stock rose 90% in the first half. That's after soaring 2,700% last year.</p>\n<p>Are more share gains on the horizon? Novavax said in its latest earnings call that it expects to generate billions of dollars in revenue over the next four to six quarters. If Novavax wins vaccine authorization in the coming months, this could become a reality. The company already has orders to deliver 200 million doses to various countries. All of this could equal solid share performance in the second half.</p>\n<p><img src=\"https://static.tigerbbs.com/54a0fc748f5a7357128a290dd852b959\" tg-width=\"720\" tg-height=\"534\" referrerpolicy=\"no-referrer\"></p>\n<p>NVAX data by YCharts</p>\n<p><b>Vaxart</b></p>\n<p>The program:&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> seemed out of the race earlier in the year. The company's phase 1 trial showed its oral vaccine candidate didn't produce neutralizing antibodies. They are seen as key to preventing infection. But additional trial data demonstrated strength in producing killer T cell responses. This powerful immune system tool is another way to fight infection. Vaxart said it would launch a phase 2 study of its candidate mid-year. It will start a phase 1/2 study of a variant-specific candidate in the third quarter.</p>\n<p>The share price: Vaxart shares climbed 31% in the first half. That follows last year's 1,500% increase.</p>\n<p>Are more share gains on the horizon? Vaxart remains risky. Any negative news in the second half could be disastrous. Still, the idea of a vaccine in pill form could be a game-changer. If the company announces trial starts as planned, the shares may outperform the market in the coming months. And any positive data could offer a major boost.</p>\n<p><b><a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b></p>\n<p>The program: Moderna reported more than $1 billion in profit -- its first profit ever -- after <a href=\"https://laohu8.com/S/AONE.U\">one</a> full quarter of coronavirus vaccine sales. The company expects at least $19.2 billion in vaccine revenue this year. It's already won 2022 orders from countries including the U.S., Israel, and Switzerland. And the company predicts need for the vaccine could be greater next year than this year.</p>\n<p>The share price: Moderna shares rose about 125% in the first half -- and added more than 40% over the past month. That's after a 434% increase last year.</p>\n<p>Are more share gains on the horizon? Moderna is likely to beat the S&amp;P 500 in the second half if three key things happen: The company reports new contracts for 2022, successfully gains authorization for the use of its vaccine in teens, and gets the regulatory nod for a booster. I'm pretty optimistic about each.</p>\n<p><b><a href=\"https://laohu8.com/S/ARCT\">Arcturus Therapeutics Ltd.</a> </b></p>\n<p>The program:<b>Arcturus Therapeutics</b> (NASDAQ:ARCT) is testing its mRNA vaccine in a phase 2 study and plans on reporting data in the second half. The product could stand out from mRNA rivals<b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b> and Moderna because it's freeze-dried and given in <a href=\"https://laohu8.com/S/AONE.U\">one</a> dose. The Pfizer and Moderna vaccines require cold storage and are given in two shots.</p>\n<p>The share price: Arcturus shares slipped 22% in the first half. Last year, they surged 299%.</p>\n<p>Is a share price recovery on the horizon? The above advantages sound great. But here's the problem: In a phase 1 study, Arcturus' candidate produced lower neutralizing antibody levels than the Pfizer and Moderna jabs. This translates into lower efficacy. If the next batch of data shows stronger results, the shares could climb. But if performance remains well below rivals, I wouldn't expect Arcturus to beat the S&amp;P 500 in the second half.</p>\n<p><img src=\"https://static.tigerbbs.com/cd5cf54e35734c9da8a1260f2c3436bc\" tg-width=\"720\" tg-height=\"534\" referrerpolicy=\"no-referrer\"></p>\n<p>NVAX data by YCharts</p>\n<p><b>Ocugen</b></p>\n<p>The program:&nbsp;<b>Ocugen</b> (NASDAQ:OCGN) in December announced it would partner with India's Bharat Biotech to co-commercialize its late-stage coronavirus vaccine in the U.S. More recently, the U.S. Food and Drug Administration advised Ocugen to pursue a traditional regulatory path rather than Emergency Use Authorization (EUA). Ocugen also gained rights to co-commercialize the candidate in Canada and has started a rolling submission there.</p>\n<p>The share price: Ocugen stock soared 338% in the first half. That's after climbing more than 251% last year (with almost all of that gain coming after the Bharat partnership announcement).</p>\n<p>Are more share gains on the horizon? Ocugen remains high risk. <a href=\"https://laohu8.com/S/ISBC\">Investors</a> were betting on big revenue from a possible EUA in the U.S. Now, revenue possibilities seem lower and farther off. The stock may continue to climb in the second half if Canada moves quickly on an authorization. But in my opinion, over the long term, the shares are like a house of cards. If U.S. approval doesn't happen or takes too long, they may collapse.</p>\n<p><b><a href=\"https://laohu8.com/S/INO\">Inovio Pharmaceuticals</a> </b></p>\n<p>The program: Earlier this year, the U.S. government dropped plans to fund<b><a href=\"https://laohu8.com/S/INO\">Inovio Pharmaceuticals</a></b>' (NASDAQ:INO) phase 3 trial. The government cited the rapid launch of other vaccines into the marketplace. As a result, Inovio said it would conduct phase 3 primarily outside of the U.S. The company aims to launch the trial with Chinese partner Advaccine Biopharmaceuticals Suzhou this summer. Inovio also is working on a next-generation \"pan-COVID\" vaccine candidate. It plans to start clinical testing on the candidate this year.</p>\n<p>The share price: Inovio added 4.8% in the first half. That's after climbing 168% last year.</p>\n<p>Are more share gains on the horizon? Inovio is another high-risk stock. Its initial candidate may have trouble carving out share in a market dominated by solid players. Most promising is the pan-COVID candidate. Especially considering the growth of variants. But we'll need clinical trial data to see if the potential product actually works. I would be surprised if Inovio beat the S&amp;P 500 in the second half of this year. The pan-COVID candidate makes Inovio a stock to watch -- but from a distance.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Can Last Year's Biggest Vaccine Stocks Crush the Market Again?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCan Last Year's Biggest Vaccine Stocks Crush the Market Again?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-02 20:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/02/can-these-big-vaccine-stocks-crush-market-again/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These players delivered triple- and quadruple-digit gains.\n\nKey Points\n\nLast year, most coronavirus vaccine stocks were high risk.\nToday, there are investment opportunities for aggressive investors ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/02/can-these-big-vaccine-stocks-crush-market-again/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","VXRT":"Vaxart, Inc","BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","OCGN":"Ocugen","INO":"伊诺维奥制药","NVAX":"诺瓦瓦克斯医药","ARCT":"Arcturus Therapeutics Ltd."},"source_url":"https://www.fool.com/investing/2021/08/02/can-these-big-vaccine-stocks-crush-market-again/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156192895","content_text":"These players delivered triple- and quadruple-digit gains.\n\nKey Points\n\nLast year, most coronavirus vaccine stocks were high risk.\nToday, there are investment opportunities for aggressive investors and cautious investors.\n\nCoronavirus vaccine stocks were the biggest investment theme of 2020. Some players soared more than 1,000% as investors bet on their abilities to bring a billion-dollar product to market. That's as the S&P 500 Index rose about 16%.\nSince, two biotech companies --Moderna (NASDAQ:MRNA) and BioNTech SE -- actually have commercialized their vaccines. And they are indeed generating billions of dollars in revenue. But what about some of the other vaccine stocks that scored big on the stock market last year? Let's take a look at where they're at with vaccine programs -- and whether they're on track to beat the market in the second half.\n\nImage source: Getty Images.\nNovavax\nThe program: Novavax's U.S. phase 3 trial of its vaccine candidate showed 90.4% overall efficacy. It demonstrated 100% efficacy in moderate and severe disease. The company fell behind in its submissions to regulators as it ramped up its manufacturing network. For instance, it's faced shortages of certain raw materials needed to produce the vaccine candidate. In May, Novavax said it would file for authorization in various locations worldwide -- including the U.S. -- in the third quarter. And Novavax predicts manufacturing will operate at full capacity as of the fourth quarter.\nThe share price: The stock rose 90% in the first half. That's after soaring 2,700% last year.\nAre more share gains on the horizon? Novavax said in its latest earnings call that it expects to generate billions of dollars in revenue over the next four to six quarters. If Novavax wins vaccine authorization in the coming months, this could become a reality. The company already has orders to deliver 200 million doses to various countries. All of this could equal solid share performance in the second half.\n\nNVAX data by YCharts\nVaxart\nThe program: Vaxart, Inc seemed out of the race earlier in the year. The company's phase 1 trial showed its oral vaccine candidate didn't produce neutralizing antibodies. They are seen as key to preventing infection. But additional trial data demonstrated strength in producing killer T cell responses. This powerful immune system tool is another way to fight infection. Vaxart said it would launch a phase 2 study of its candidate mid-year. It will start a phase 1/2 study of a variant-specific candidate in the third quarter.\nThe share price: Vaxart shares climbed 31% in the first half. That follows last year's 1,500% increase.\nAre more share gains on the horizon? Vaxart remains risky. Any negative news in the second half could be disastrous. Still, the idea of a vaccine in pill form could be a game-changer. If the company announces trial starts as planned, the shares may outperform the market in the coming months. And any positive data could offer a major boost.\nModerna, Inc.\nThe program: Moderna reported more than $1 billion in profit -- its first profit ever -- after one full quarter of coronavirus vaccine sales. The company expects at least $19.2 billion in vaccine revenue this year. It's already won 2022 orders from countries including the U.S., Israel, and Switzerland. And the company predicts need for the vaccine could be greater next year than this year.\nThe share price: Moderna shares rose about 125% in the first half -- and added more than 40% over the past month. That's after a 434% increase last year.\nAre more share gains on the horizon? Moderna is likely to beat the S&P 500 in the second half if three key things happen: The company reports new contracts for 2022, successfully gains authorization for the use of its vaccine in teens, and gets the regulatory nod for a booster. I'm pretty optimistic about each.\nArcturus Therapeutics Ltd. \nThe program:Arcturus Therapeutics (NASDAQ:ARCT) is testing its mRNA vaccine in a phase 2 study and plans on reporting data in the second half. The product could stand out from mRNA rivalsPfizer and Moderna because it's freeze-dried and given in one dose. The Pfizer and Moderna vaccines require cold storage and are given in two shots.\nThe share price: Arcturus shares slipped 22% in the first half. Last year, they surged 299%.\nIs a share price recovery on the horizon? The above advantages sound great. But here's the problem: In a phase 1 study, Arcturus' candidate produced lower neutralizing antibody levels than the Pfizer and Moderna jabs. This translates into lower efficacy. If the next batch of data shows stronger results, the shares could climb. But if performance remains well below rivals, I wouldn't expect Arcturus to beat the S&P 500 in the second half.\n\nNVAX data by YCharts\nOcugen\nThe program: Ocugen (NASDAQ:OCGN) in December announced it would partner with India's Bharat Biotech to co-commercialize its late-stage coronavirus vaccine in the U.S. More recently, the U.S. Food and Drug Administration advised Ocugen to pursue a traditional regulatory path rather than Emergency Use Authorization (EUA). Ocugen also gained rights to co-commercialize the candidate in Canada and has started a rolling submission there.\nThe share price: Ocugen stock soared 338% in the first half. That's after climbing more than 251% last year (with almost all of that gain coming after the Bharat partnership announcement).\nAre more share gains on the horizon? Ocugen remains high risk. Investors were betting on big revenue from a possible EUA in the U.S. Now, revenue possibilities seem lower and farther off. The stock may continue to climb in the second half if Canada moves quickly on an authorization. But in my opinion, over the long term, the shares are like a house of cards. If U.S. approval doesn't happen or takes too long, they may collapse.\nInovio Pharmaceuticals \nThe program: Earlier this year, the U.S. government dropped plans to fundInovio Pharmaceuticals' (NASDAQ:INO) phase 3 trial. The government cited the rapid launch of other vaccines into the marketplace. As a result, Inovio said it would conduct phase 3 primarily outside of the U.S. The company aims to launch the trial with Chinese partner Advaccine Biopharmaceuticals Suzhou this summer. Inovio also is working on a next-generation \"pan-COVID\" vaccine candidate. It plans to start clinical testing on the candidate this year.\nThe share price: Inovio added 4.8% in the first half. That's after climbing 168% last year.\nAre more share gains on the horizon? Inovio is another high-risk stock. Its initial candidate may have trouble carving out share in a market dominated by solid players. Most promising is the pan-COVID candidate. Especially considering the growth of variants. But we'll need clinical trial data to see if the potential product actually works. I would be surprised if Inovio beat the S&P 500 in the second half of this year. The pan-COVID candidate makes Inovio a stock to watch -- but from a distance.","news_type":1},"isVote":1,"tweetType":1,"viewCount":158,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":810626892,"gmtCreate":1629973702016,"gmtModify":1676530188636,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/810626892","repostId":"2162060923","repostType":4,"isVote":1,"tweetType":1,"viewCount":196,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":830574407,"gmtCreate":1629086128209,"gmtModify":1676529925079,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/830574407","repostId":"1145684106","repostType":4,"isVote":1,"tweetType":1,"viewCount":514,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":172655858,"gmtCreate":1626960649474,"gmtModify":1703481379482,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/172655858","repostId":"1170462111","repostType":4,"isVote":1,"tweetType":1,"viewCount":71,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":807096428,"gmtCreate":1627986787164,"gmtModify":1703499123034,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Woe","listText":"Woe","text":"Woe","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/807096428","repostId":"2156100119","repostType":4,"isVote":1,"tweetType":1,"viewCount":227,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":811806284,"gmtCreate":1630304774548,"gmtModify":1676530262622,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Ho","listText":"Ho","text":"Ho","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/811806284","repostId":"2163776380","repostType":4,"repost":{"id":"2163776380","kind":"news","pubTimestamp":1630268536,"share":"https://ttm.financial/m/news/2163776380?lang=&edition=fundamental","pubTime":"2021-08-30 04:22","market":"other","language":"en","title":"August jobs report, Consumer confidence: What to know this week","url":"https://stock-news.laohu8.com/highlight/detail?id=2163776380","media":"Yahoo Finance","summary":"New data on the U.S. labor market will be in focus this week, offering an updated look at how economic activity has been impacted as the spread of the Delta variant ramped up in the U.S. over the summer.The Labor Department's August jobs report will be the marquee economic report out this week. Consensus economists expect to see that a still-robust 750,000 jobs came back in August, according to Bloomberg data. This would represent a significant print by pre-pandemic standards, but still mark a d","content":"<p>New data on the U.S. labor market will be in focus this week, offering an updated look at how economic activity has been impacted as the spread of the Delta variant ramped up in the U.S. over the summer.</p>\n<p>The Labor Department's August jobs report will be the marquee economic report out this week. Consensus economists expect to see that a still-robust 750,000 jobs came back in August, according to Bloomberg data. This would represent a significant print by pre-pandemic standards, but still mark a deceleration from July's increase of 943,000 jobs. The unemployment rate likely improved further, reaching 5.2% from the 5.4% reported during July.</p>\n<p>The August jobs report is set to be an especially telling report, capturing the impact of the latest surge in coronavirus cases on the U.S. labor market. Other recent economic reports already began to reflect the Delta variant impacts on activity: Job creation in the U.S. services sector slowed by the most since February, while manufacturing sector workforce numbers increased by the least since last year, according to IHS <a href=\"https://laohu8.com/S/MRKT\">Markit</a>'s latest purchasing managers' index reports.</p>\n<p>\"High frequency labor market data are signaling a marked slowdown in employment activity in the August payroll survey week, suggesting downside risk to our forecast,\" Bank of America economist Michelle Meyer wrote in a note on Friday, adding that she expects non-farm payrolls to grow by just 600,000 for August.</p>\n<p>\"Our below-consensus non-farm payrolls forecast is predicated on the markedly weaker high frequency employment data between the July and August payroll survey periods,\" Meyer added. \"Specifically, the Homebase and UKG employment series were both down 3.4% and 2.4%, respectively, over the month.\"</p>\n<p>The outcome of the August jobs report will also be another closely watched data point informing the Federal Reserve's next moves on monetary policy, signaling whether the labor market has recovered enough to warrant a less accommodative tilt. Namely, many Fed officials have been waiting to see the evolution of the labor market recovery to determine the timing for the central bank to announce tapering of its $120 billion per month asset purchase program.</p>\n<p>Last week, Federal Reserve Chair Jerome Powell said during the central bank's virtual Jackson Hole symposium that there has \"been clear progress toward maximum employment\" and suggested \"it could be appropriate to start reducing the pace of asset purchases this year\" if the recovery continues to improve.</p>\n<p>However, he also flagged the ongoing risks introduced by the Delta variant, and added that an \"ill-time policy move\" could knock the recovery off its trajectory.</p>\n<p><img src=\"https://static.tigerbbs.com/67ac641337acd82a0408b6109dad21f9\" tg-width=\"5505\" tg-height=\"3655\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\">NEW YORK, NEW YORK - MAY 27: People walk near Little Island park on May 27, 2021 in New York City. On May 19, all pandemic restrictions, including mask mandates, social distancing guidelines, venue capacities and restaurant curfews were lifted by New York Governor Andrew Cuomo. (Photo by Noam Galai/Getty Images)Noam Galai via Getty Images</p>\n<p>\"Given the emphasis that Powell and other FOMC members have placed on incoming data — especially on the labor market — the payrolls report will probably take on even greater importance than usual,\" Jonas Goltermann, senior markets economist for Capital Economics, wrote in a note on Friday. \"We expect another robust increase in U.S. employment,\"</p>\n<p>Other data in Friday's jobs report will include average hourly wage changes. These are expected to grow 0.3% over last month and 4.0% over last year, with these paces remaining roughly unchanged compared to July. The increases are set to come as job growth slows across lower-wage roles after an initial reopening surge in hiring in the spring and early summer, and as worker shortages push up compensation costs across many firms.</p>\n<h3>Consumer confidence</h3>\n<p>Other economic data due for release this week will reflect consumers' assessments of the recovery.</p>\n<p>The Conference Board's consumer confidence index is set for release on Tuesday, with a drop baked into the forecast. Consensus economists expect the index to slip to 123.0 for August, down from 129.1 in July, according to Bloomberg data. July's print had been the highest since February 2020, marking a rebound in confidence back to pre-pandemic levels.</p>\n<p>The Conference Board's labor differential, or difference between those who said jobs are \"plentiful\" less those who said jobs were \"hard to get,\" also increased to the most since 2000 in last month's report, pointing to the abundance of job openings as employers seek out workers to meet rising demand.</p>\n<p>Consumer confidence and sentiment indices have been monitored closely this year as a gauge of the outlook among Americans at large, pointing to consumers' propensity to spend and presaging demand trends for goods, services and labor down the line. The data have been bumpy in recent months, however, and have ebbed and flowed largely in line with COVID-19 infection trends.</p>\n<p>The latest surge in the Delta variant catalyzed a collapse in the University of Michigan's Surveys of Consumers index for August, suggesting the Conference Board's measure might also see a similar dip for the month. The University of Michigan's consumer sentiment index slid to a 10-year low in August, plunging to 70.3 from July's 81.2.</p>\n<p>\"Consumers' extreme reactions were due to the surging Delta variant, higher inflation, slower wage growth, and smaller declines in unemployment,\" Richard Curtin, Surveys of Consumers chief economist, wrote in a press statement. \"The extraordinary falloff in sentiment also reflects an emotional response, from dashed hopes that the pandemic would soon end and lives could return to normal.\"</p>\n<h3>Economic calendar</h3>\n<ul>\n <li><p><b>Monday: </b>Pending home sales, month-over-month, July (0.4% expected, -1.9% in June); Dallas Fed Manufacturing Activity index, August (23.0 expected, 27.3 in July)</p></li>\n <li><p><b>Tuesday: </b>FHFA Home Price index, month-over-month, June (1.9% expected, 1.7% in May); S&amp;P <a href=\"https://laohu8.com/S/CLGX\">CoreLogic</a> Case-Shiller 20-City index, month-over-month, June (1.87% expected, 1.81% in May); S&amp;P CoreLogic Case-Shiller 20-City index, year-over-year, June (18.60% expected, 16.99% in May); MNI Chicago PMI, August (68.0 expected, 73.4 in July); Conference Board Consumer Confidence, August (123.4 expected, 129.1 in July)</p></li>\n <li><p><b>Wednesday: </b>MBA Mortgage Applications, week ended August 27 (1.6% during prior week); ADP employment change, August (650,000 expected, 330,000 in July); Markit U.S. Manufacturing PMI, August final (61.2 expected, 61.2 in prior print); Construction spending, month-over-month (0.2% expected, 0.1% in June); ISM Manufacturing index, August (58.5 expected, 59.5 in July)</p></li>\n <li><p><b>Thursday: </b>Challenger Job Cuts, year-over-year, August (-92.8% in July); Initial jobless claims, week ended August 28 (346,000 expected, 353,000 during prior week); Continuing claims, week ended August 21 (2.862 million during prior week); Unit labor costs, 2Q final (1.0% expected, 1.0% in prior print); Trade balance, July (-$74.1 billion expected, -$75.7 billion in June); Factory orders, July (0.3% expected, 1.5% in June); Durable goods orders, July final (-0.1% in prior print); Non-defense capital goods orders, excluding aircraft, July final (0.0% in prior print); Non-defense capital goods shipments, July final (1.0% in prior print)</p></li>\n <li><p><b>Friday: </b>Change in non-farm payrolls, August (750,000 expected, 943,000 in July); Change in manufacturing payrolls, August (700,000 expected, 703,000 in July); Unemployment rate, August (5.2% expected, 5.4% in July); Average hourly earnings, month-over-month, August (0.3% expected, 0.4% in July); Average hourly earnings, year-over-year, August (3.9% expected, 4.0% in July); Markit U.S. services PMI, August final (55.2 expected, 55.2 in prior print); Markit U.S. composite PMI, August final (55.4 in prior print); ISM Services Index, August (62.0 expected, 64.1 in July)</p></li>\n</ul>\n<h2>Earnings calendar</h2>\n<ul>\n <li><p><b>Monday: </b><a href=\"https://laohu8.com/S/ZM\">Zoom</a> Video Communications (ZM) after market close</p></li>\n <li><p><b>Tuesday: </b>Crowdstrike (CRWD) after market close</p></li>\n <li><p><b>Wednesday: </b>Campbell Soup (CPB) before market open; Okta (OKTA), Chewy (CHWY), C3.ai (AI), Asana (ASAN) after market close</p></li>\n <li><p><b>Thursday: </b>American Eagle Outfitters (AEO) before market open; Broadcom (AVGO), DocuSign (DOCU), MongoDB (MDB) after market close</p></li>\n <li><p><b>Friday:</b><i> </i>No notable reports scheduled for release</p></li>\n</ul>","source":"yahoofinance_au","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>August jobs report, Consumer confidence: What to know this week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAugust jobs report, Consumer confidence: What to know this week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-30 04:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/august-jobs-report-consumer-confidence-what-to-know-this-week-202216254.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>New data on the U.S. labor market will be in focus this week, offering an updated look at how economic activity has been impacted as the spread of the Delta variant ramped up in the U.S. over the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/august-jobs-report-consumer-confidence-what-to-know-this-week-202216254.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/650fad7fca15e203aa26611c0dfb8d62","relate_stocks":{"WMT":"沃尔玛","TGT":"塔吉特","XRT":"零售指数ETF-SPDR标普","SPY.AU":"SPDR® S&P 500® ETF Trust"},"source_url":"https://finance.yahoo.com/news/august-jobs-report-consumer-confidence-what-to-know-this-week-202216254.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2163776380","content_text":"New data on the U.S. labor market will be in focus this week, offering an updated look at how economic activity has been impacted as the spread of the Delta variant ramped up in the U.S. over the summer.\nThe Labor Department's August jobs report will be the marquee economic report out this week. Consensus economists expect to see that a still-robust 750,000 jobs came back in August, according to Bloomberg data. This would represent a significant print by pre-pandemic standards, but still mark a deceleration from July's increase of 943,000 jobs. The unemployment rate likely improved further, reaching 5.2% from the 5.4% reported during July.\nThe August jobs report is set to be an especially telling report, capturing the impact of the latest surge in coronavirus cases on the U.S. labor market. Other recent economic reports already began to reflect the Delta variant impacts on activity: Job creation in the U.S. services sector slowed by the most since February, while manufacturing sector workforce numbers increased by the least since last year, according to IHS Markit's latest purchasing managers' index reports.\n\"High frequency labor market data are signaling a marked slowdown in employment activity in the August payroll survey week, suggesting downside risk to our forecast,\" Bank of America economist Michelle Meyer wrote in a note on Friday, adding that she expects non-farm payrolls to grow by just 600,000 for August.\n\"Our below-consensus non-farm payrolls forecast is predicated on the markedly weaker high frequency employment data between the July and August payroll survey periods,\" Meyer added. \"Specifically, the Homebase and UKG employment series were both down 3.4% and 2.4%, respectively, over the month.\"\nThe outcome of the August jobs report will also be another closely watched data point informing the Federal Reserve's next moves on monetary policy, signaling whether the labor market has recovered enough to warrant a less accommodative tilt. Namely, many Fed officials have been waiting to see the evolution of the labor market recovery to determine the timing for the central bank to announce tapering of its $120 billion per month asset purchase program.\nLast week, Federal Reserve Chair Jerome Powell said during the central bank's virtual Jackson Hole symposium that there has \"been clear progress toward maximum employment\" and suggested \"it could be appropriate to start reducing the pace of asset purchases this year\" if the recovery continues to improve.\nHowever, he also flagged the ongoing risks introduced by the Delta variant, and added that an \"ill-time policy move\" could knock the recovery off its trajectory.\nNEW YORK, NEW YORK - MAY 27: People walk near Little Island park on May 27, 2021 in New York City. On May 19, all pandemic restrictions, including mask mandates, social distancing guidelines, venue capacities and restaurant curfews were lifted by New York Governor Andrew Cuomo. (Photo by Noam Galai/Getty Images)Noam Galai via Getty Images\n\"Given the emphasis that Powell and other FOMC members have placed on incoming data — especially on the labor market — the payrolls report will probably take on even greater importance than usual,\" Jonas Goltermann, senior markets economist for Capital Economics, wrote in a note on Friday. \"We expect another robust increase in U.S. employment,\"\nOther data in Friday's jobs report will include average hourly wage changes. These are expected to grow 0.3% over last month and 4.0% over last year, with these paces remaining roughly unchanged compared to July. The increases are set to come as job growth slows across lower-wage roles after an initial reopening surge in hiring in the spring and early summer, and as worker shortages push up compensation costs across many firms.\nConsumer confidence\nOther economic data due for release this week will reflect consumers' assessments of the recovery.\nThe Conference Board's consumer confidence index is set for release on Tuesday, with a drop baked into the forecast. Consensus economists expect the index to slip to 123.0 for August, down from 129.1 in July, according to Bloomberg data. July's print had been the highest since February 2020, marking a rebound in confidence back to pre-pandemic levels.\nThe Conference Board's labor differential, or difference between those who said jobs are \"plentiful\" less those who said jobs were \"hard to get,\" also increased to the most since 2000 in last month's report, pointing to the abundance of job openings as employers seek out workers to meet rising demand.\nConsumer confidence and sentiment indices have been monitored closely this year as a gauge of the outlook among Americans at large, pointing to consumers' propensity to spend and presaging demand trends for goods, services and labor down the line. The data have been bumpy in recent months, however, and have ebbed and flowed largely in line with COVID-19 infection trends.\nThe latest surge in the Delta variant catalyzed a collapse in the University of Michigan's Surveys of Consumers index for August, suggesting the Conference Board's measure might also see a similar dip for the month. The University of Michigan's consumer sentiment index slid to a 10-year low in August, plunging to 70.3 from July's 81.2.\n\"Consumers' extreme reactions were due to the surging Delta variant, higher inflation, slower wage growth, and smaller declines in unemployment,\" Richard Curtin, Surveys of Consumers chief economist, wrote in a press statement. \"The extraordinary falloff in sentiment also reflects an emotional response, from dashed hopes that the pandemic would soon end and lives could return to normal.\"\nEconomic calendar\n\nMonday: Pending home sales, month-over-month, July (0.4% expected, -1.9% in June); Dallas Fed Manufacturing Activity index, August (23.0 expected, 27.3 in July)\nTuesday: FHFA Home Price index, month-over-month, June (1.9% expected, 1.7% in May); S&P CoreLogic Case-Shiller 20-City index, month-over-month, June (1.87% expected, 1.81% in May); S&P CoreLogic Case-Shiller 20-City index, year-over-year, June (18.60% expected, 16.99% in May); MNI Chicago PMI, August (68.0 expected, 73.4 in July); Conference Board Consumer Confidence, August (123.4 expected, 129.1 in July)\nWednesday: MBA Mortgage Applications, week ended August 27 (1.6% during prior week); ADP employment change, August (650,000 expected, 330,000 in July); Markit U.S. Manufacturing PMI, August final (61.2 expected, 61.2 in prior print); Construction spending, month-over-month (0.2% expected, 0.1% in June); ISM Manufacturing index, August (58.5 expected, 59.5 in July)\nThursday: Challenger Job Cuts, year-over-year, August (-92.8% in July); Initial jobless claims, week ended August 28 (346,000 expected, 353,000 during prior week); Continuing claims, week ended August 21 (2.862 million during prior week); Unit labor costs, 2Q final (1.0% expected, 1.0% in prior print); Trade balance, July (-$74.1 billion expected, -$75.7 billion in June); Factory orders, July (0.3% expected, 1.5% in June); Durable goods orders, July final (-0.1% in prior print); Non-defense capital goods orders, excluding aircraft, July final (0.0% in prior print); Non-defense capital goods shipments, July final (1.0% in prior print)\nFriday: Change in non-farm payrolls, August (750,000 expected, 943,000 in July); Change in manufacturing payrolls, August (700,000 expected, 703,000 in July); Unemployment rate, August (5.2% expected, 5.4% in July); Average hourly earnings, month-over-month, August (0.3% expected, 0.4% in July); Average hourly earnings, year-over-year, August (3.9% expected, 4.0% in July); Markit U.S. services PMI, August final (55.2 expected, 55.2 in prior print); Markit U.S. composite PMI, August final (55.4 in prior print); ISM Services Index, August (62.0 expected, 64.1 in July)\n\nEarnings calendar\n\nMonday: Zoom Video Communications (ZM) after market close\nTuesday: Crowdstrike (CRWD) after market close\nWednesday: Campbell Soup (CPB) before market open; Okta (OKTA), Chewy (CHWY), C3.ai (AI), Asana (ASAN) after market close\nThursday: American Eagle Outfitters (AEO) before market open; Broadcom (AVGO), DocuSign (DOCU), MongoDB (MDB) after market close\nFriday: No notable reports scheduled for release","news_type":1},"isVote":1,"tweetType":1,"viewCount":366,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":819191431,"gmtCreate":1630040786423,"gmtModify":1676530208375,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Mive","listText":"Mive","text":"Mive","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/819191431","repostId":"2162847016","repostType":4,"repost":{"id":"2162847016","kind":"news","pubTimestamp":1630008724,"share":"https://ttm.financial/m/news/2162847016?lang=&edition=fundamental","pubTime":"2021-08-27 04:12","market":"us","language":"en","title":"Wall Street loses ground, snapping rally on Afghanistan, Fed concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2162847016","media":"Reuters","summary":"NEW YORK, Aug 26 (Reuters) - Wall Street closed lower on Thursday, ending a streak of all-time closi","content":"<p>NEW YORK, Aug 26 (Reuters) - Wall Street closed lower on Thursday, ending a streak of all-time closing highs on concerns over developments in Afghanistan, while fears of a potential shift in U.S. Federal Reserve policy prompted a broad but shallow sell-off the day before the Jackson Hole Symposium.</p>\n<p>All three major U.S. stock indexes ended the session in the red, with the S&amp;P and the Nasdaq notching their first down day in six.</p>\n<p>The sell-off firmed after hawkish commentary from Dallas Fed President Robert Kaplan and a blast outside the Kabul airport in Afghanistan helped strengthen the risk-off sentiment.</p>\n<p>Kaplan, who is not currently a voting member of the Federal Open Markets Committee, said he believes the progress of economic recovery warrants tapering of the Fed's asset purchases to commence in October or shortly thereafter.</p>\n<p>Kaplan's remarks followed earlier comments from the St. Louis Fed President James Bullard, who said that the central bank is \"coalescing\" around a plan to begin tapering process.</p>\n<p>\"(Kaplan’s statements) caused a little confusion about the taper timeline, but in my opinion the equity markets are focused on geopolitical issues,\" said Megan Horneman, director of portfolio strategy at Verdence Capital Advisors in Hunt Valley, Maryland. \"There’s a flight to safety during geopolitical tensions.\"</p>\n<p>\"I am surprised the market the market hasn’t fallen more, given the fear that it could take focus away from (U.S. President Joe Biden's) domestic agenda,\" Horneman added.</p>\n<p>The economy grew at a slightly faster pace than originally reported in the second quarter, fully recovering its losses from the most abrupt downturn in U.S. history, according to the Commerce Department. But jobless claims, though still on a downward trajectory, ticked higher last week.</p>\n<p>The data did little to move the needle with respect to expectations that the Fed is unlikely tip its hand regarding the taper timeline when Chairman Jerome Powell unmutes and delivers his speech at Friday's virtual Jackson Hole Symposium.</p>\n<p>\"We’re going to see a lot of market participants analyze every word (Powell) uses, but at the end of the day, they will begin tapering,\" Horneman said. \"I’m more concerned about the speed at which they taper. What are they going to start with? That will give us a clearer indication as whether they’re getting more hawkish.\"</p>\n<p>The Dow Jones Industrial Average fell 192.38 points, or 0.54%, to 35,213.12, the S&amp;P 500 lost 26.19 points, or 0.58%, to 4,470 and the Nasdaq Composite dropped 96.05 points, or 0.64%, to 14,945.81.</p>\n<p>Of the 11 major sectors in the S&amp;P 500, all but real estate ended the session lower, with energy stocks suffering the steepest percentage loss.</p>\n<p>Discount retailers Dollar General Corp and Dollar Tree Inc slid 3.8% and 12.1%, respectively, after warning higher transportation costs will hurt their bottom lines.</p>\n<p>Coty Inc jumped 14.7% after the cosmetics firm said it expects to post full-year sales growth for the first time in three years.</p>\n<p>Salesforce.com Inc hiked its earnings forecast as the shift to a hybrid work model is expected to fuel strong demand. Its shares advanced 2.7%.</p>\n<p>NetApp Inc jumped 4.7% as brokerages raised their price targets in the wake of the cloud computing firm's better-than-expected 2022 earnings outlook.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 2.99-to-1 ratio; on Nasdaq, a 1.83-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 31 new 52-week highs and two new lows; the Nasdaq Composite recorded 82 new highs and 39 new lows.</p>\n<p>Volume on U.S. exchanges was 8.27 billion shares, compared with the 8.96 billion average over the last 20 trading days. (Reporting by Stephen Culp; Additional reporting by Devik Jain in Bengaluru Editing by Marguerita Choy)</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street loses ground, snapping rally on Afghanistan, Fed concerns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street loses ground, snapping rally on Afghanistan, Fed concerns\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-27 04:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/us-stocks-wall-street-loses-201204459.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK, Aug 26 (Reuters) - Wall Street closed lower on Thursday, ending a streak of all-time closing highs on concerns over developments in Afghanistan, while fears of a potential shift in U.S. ...</p>\n\n<a href=\"https://finance.yahoo.com/news/us-stocks-wall-street-loses-201204459.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","OEX":"标普100","IVV":"标普500指数ETF","SDS":"两倍做空标普500ETF","UPRO":"三倍做多标普500ETF",".SPX":"S&P 500 Index","SPXU":"三倍做空标普500ETF","SSO":"两倍做多标普500ETF","COMP":"Compass, Inc.","SH":"标普500反向ETF","OEF":"标普100指数ETF-iShares"},"source_url":"https://finance.yahoo.com/news/us-stocks-wall-street-loses-201204459.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2162847016","content_text":"NEW YORK, Aug 26 (Reuters) - Wall Street closed lower on Thursday, ending a streak of all-time closing highs on concerns over developments in Afghanistan, while fears of a potential shift in U.S. Federal Reserve policy prompted a broad but shallow sell-off the day before the Jackson Hole Symposium.\nAll three major U.S. stock indexes ended the session in the red, with the S&P and the Nasdaq notching their first down day in six.\nThe sell-off firmed after hawkish commentary from Dallas Fed President Robert Kaplan and a blast outside the Kabul airport in Afghanistan helped strengthen the risk-off sentiment.\nKaplan, who is not currently a voting member of the Federal Open Markets Committee, said he believes the progress of economic recovery warrants tapering of the Fed's asset purchases to commence in October or shortly thereafter.\nKaplan's remarks followed earlier comments from the St. Louis Fed President James Bullard, who said that the central bank is \"coalescing\" around a plan to begin tapering process.\n\"(Kaplan’s statements) caused a little confusion about the taper timeline, but in my opinion the equity markets are focused on geopolitical issues,\" said Megan Horneman, director of portfolio strategy at Verdence Capital Advisors in Hunt Valley, Maryland. \"There’s a flight to safety during geopolitical tensions.\"\n\"I am surprised the market the market hasn’t fallen more, given the fear that it could take focus away from (U.S. President Joe Biden's) domestic agenda,\" Horneman added.\nThe economy grew at a slightly faster pace than originally reported in the second quarter, fully recovering its losses from the most abrupt downturn in U.S. history, according to the Commerce Department. But jobless claims, though still on a downward trajectory, ticked higher last week.\nThe data did little to move the needle with respect to expectations that the Fed is unlikely tip its hand regarding the taper timeline when Chairman Jerome Powell unmutes and delivers his speech at Friday's virtual Jackson Hole Symposium.\n\"We’re going to see a lot of market participants analyze every word (Powell) uses, but at the end of the day, they will begin tapering,\" Horneman said. \"I’m more concerned about the speed at which they taper. What are they going to start with? That will give us a clearer indication as whether they’re getting more hawkish.\"\nThe Dow Jones Industrial Average fell 192.38 points, or 0.54%, to 35,213.12, the S&P 500 lost 26.19 points, or 0.58%, to 4,470 and the Nasdaq Composite dropped 96.05 points, or 0.64%, to 14,945.81.\nOf the 11 major sectors in the S&P 500, all but real estate ended the session lower, with energy stocks suffering the steepest percentage loss.\nDiscount retailers Dollar General Corp and Dollar Tree Inc slid 3.8% and 12.1%, respectively, after warning higher transportation costs will hurt their bottom lines.\nCoty Inc jumped 14.7% after the cosmetics firm said it expects to post full-year sales growth for the first time in three years.\nSalesforce.com Inc hiked its earnings forecast as the shift to a hybrid work model is expected to fuel strong demand. Its shares advanced 2.7%.\nNetApp Inc jumped 4.7% as brokerages raised their price targets in the wake of the cloud computing firm's better-than-expected 2022 earnings outlook.\nDeclining issues outnumbered advancing ones on the NYSE by a 2.99-to-1 ratio; on Nasdaq, a 1.83-to-1 ratio favored decliners.\nThe S&P 500 posted 31 new 52-week highs and two new lows; the Nasdaq Composite recorded 82 new highs and 39 new lows.\nVolume on U.S. exchanges was 8.27 billion shares, compared with the 8.96 billion average over the last 20 trading days. (Reporting by Stephen Culp; Additional reporting by Devik Jain in Bengaluru Editing by Marguerita Choy)","news_type":1},"isVote":1,"tweetType":1,"viewCount":298,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":833385441,"gmtCreate":1629206272683,"gmtModify":1676529965262,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/833385441","repostId":"1156515289","repostType":4,"isVote":1,"tweetType":1,"viewCount":429,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":898522282,"gmtCreate":1628512908346,"gmtModify":1703507317392,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/898522282","repostId":"1122651143","repostType":4,"repost":{"id":"1122651143","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628508488,"share":"https://ttm.financial/m/news/1122651143?lang=&edition=fundamental","pubTime":"2021-08-09 19:28","market":"us","language":"en","title":"Crypto sector stocks rose in premarket trading,BTCM shares jumped more than 30%,BITF surged more than 20%.","url":"https://stock-news.laohu8.com/highlight/detail?id=1122651143","media":"Tiger Newspress","summary":"Crypto sector stocks rose in premarket trading,BTCM shares jumped more than 30%,BITF surged more tha","content":"<p>Crypto&nbsp;sector&nbsp;stocks&nbsp;rose&nbsp;in&nbsp;premarket&nbsp;trading,BTCM&nbsp;shares&nbsp;jumped&nbsp;more&nbsp;than&nbsp;30%,BITF&nbsp;surged&nbsp;more&nbsp;than&nbsp;20%.</p>\n<p><img src=\"https://static.tigerbbs.com/9ece56572cf91d8de69991add19a22f4\" tg-width=\"1287\" tg-height=\"619\" referrerpolicy=\"no-referrer\">Investors in stock trading platforms are citing the momentum in cryptocurrencies as being the driving force for the stock price increase. The price of the Bitcoin cryptocurrency is up more than 9% over the past week. And Ethereum is up more than 12% over the past week.</p>\n<p>Late last month, BIT Mining announced it entered into a definitive purchase agreement to buy 2,500 new bitcoin mining machines for a total consideration of approximately US$6.6 million. And when deployed, the company expects the Acquired Machines to increase its theoretical maximum total hash rate capacity by about 165 peta hashes per second (PH/s).</p>\n<p>The acquired machines are expected to be delivered within one week from today. And following delivery, the company plans for them to be shipped to Kazakhstan for deployment.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Crypto sector stocks rose in premarket trading,BTCM shares jumped more than 30%,BITF surged more than 20%.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCrypto sector stocks rose in premarket trading,BTCM shares jumped more than 30%,BITF surged more than 20%.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-09 19:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Crypto&nbsp;sector&nbsp;stocks&nbsp;rose&nbsp;in&nbsp;premarket&nbsp;trading,BTCM&nbsp;shares&nbsp;jumped&nbsp;more&nbsp;than&nbsp;30%,BITF&nbsp;surged&nbsp;more&nbsp;than&nbsp;20%.</p>\n<p><img src=\"https://static.tigerbbs.com/9ece56572cf91d8de69991add19a22f4\" tg-width=\"1287\" tg-height=\"619\" referrerpolicy=\"no-referrer\">Investors in stock trading platforms are citing the momentum in cryptocurrencies as being the driving force for the stock price increase. The price of the Bitcoin cryptocurrency is up more than 9% over the past week. And Ethereum is up more than 12% over the past week.</p>\n<p>Late last month, BIT Mining announced it entered into a definitive purchase agreement to buy 2,500 new bitcoin mining machines for a total consideration of approximately US$6.6 million. And when deployed, the company expects the Acquired Machines to increase its theoretical maximum total hash rate capacity by about 165 peta hashes per second (PH/s).</p>\n<p>The acquired machines are expected to be delivered within one week from today. And following delivery, the company plans for them to be shipped to Kazakhstan for deployment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BITF":"Bitfarms Ltd.","BTCM":"BIT Mining"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122651143","content_text":"Crypto sector stocks rose in premarket trading,BTCM shares jumped more than 30%,BITF surged more than 20%.\nInvestors in stock trading platforms are citing the momentum in cryptocurrencies as being the driving force for the stock price increase. The price of the Bitcoin cryptocurrency is up more than 9% over the past week. And Ethereum is up more than 12% over the past week.\nLate last month, BIT Mining announced it entered into a definitive purchase agreement to buy 2,500 new bitcoin mining machines for a total consideration of approximately US$6.6 million. And when deployed, the company expects the Acquired Machines to increase its theoretical maximum total hash rate capacity by about 165 peta hashes per second (PH/s).\nThe acquired machines are expected to be delivered within one week from today. And following delivery, the company plans for them to be shipped to Kazakhstan for deployment.","news_type":1},"isVote":1,"tweetType":1,"viewCount":225,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":899807224,"gmtCreate":1628172113068,"gmtModify":1703502544208,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/899807224","repostId":"1102705333","repostType":4,"repost":{"id":"1102705333","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628170059,"share":"https://ttm.financial/m/news/1102705333?lang=&edition=fundamental","pubTime":"2021-08-05 21:27","market":"us","language":"en","title":"Stocks open slightly higher after fall in jobless claims","url":"https://stock-news.laohu8.com/highlight/detail?id=1102705333","media":"Tiger Newspress","summary":"(Aug 5) Stocks open slightly higher after fall in jobless claims.\nDow industrials up 94 points, or 0","content":"<p>(Aug 5)&nbsp;Stocks open slightly higher after fall in jobless claims.</p>\n<p>Dow industrials up 94 points, or 0.3%.&nbsp;S&amp;P 500 up 0.3% at 4,414.12.&nbsp;Nasdaq Composite up less than 0.1% at 14,784.61.&nbsp;</p>\n<p>Fastly plunges over&nbsp;23% in morning trading&nbsp;after the company's downside Q3 and full-year guidance due to the widespread outage in June.</p>\n<p><img src=\"https://static.tigerbbs.com/44fbcf9492918a352919cdff1fd27498\" tg-width=\"727\" tg-height=\"497\" width=\"100%\" height=\"auto\"></p>\n<p>The moves in the stocks came after a mostly lower regular session on Wednesday. The Dow dropped more than 300 points, or 0.9%, and closed near its session low. The S&amp;P 500 slipped about 0.5%, while the Nasdaq Composite ticked up 0.1%.</p>\n<p>Weekly initial jobless claims came in at385,000 on Thursday,in-line with expectations. Recent earnings and economic data have been strong overall, but some economists worry economic growth and employment gains will taper from here.</p>\n<p>The jobless claims data was the last reading before the key July jobs report, which will be released on Friday morning. There is a wide range of estimates from economists and what the report will show, and some metrics for employment gains have disappointed despite a high level of reported job openings.</p>\n<p>\"Many factors are likely driving worker shortages; concerns about catching the virus, childcare responsibilities, skills mismatches, and generous unemployment insurance benefits,\" PNC Senior Economist Abbey Omodunbi said in an email. In the second half of the year, \"more competition for workers, particularly in the leisure and hospitality sector, will support acceleration in wage growth, boosting household incomes and consumer spending.\"</p>\n<p>The results of an ADP private payroll survey released Wednesday showed again of 330,000 jobs for July,well short of the consensus estimate of 653,000. The Labor Department's official jobs report, which typically has more impact on investors, will be released on Friday. Economists expect the report will show the U.S. added 845,000 in non-farm payrolls in July, about even with the previous month, according to Dow Jones estimates.</p>\n<p>The10-year Treasury yieldwas holding steady near 1.8% on Thursday. The yield briefly dipping below 1.13% on Wednesday before bouncing back in late morning trading.</p>\n<p>Shares ofRokudropped 6% after the company issued quarterly results.Etsyfell 12% in early trading after the company gave guidance for the current quarter that indicated the pandemic-fueled commerce boommay be coming to an end.</p>\n<p>However, earnings season has been strong overall. Goldman Sachs raised its year-end target for the S&amp;P 500 to 4,700, representing 7% upside, in part due to an improving earnings outlook going.</p>\n<p>During regular trading Wednesday, shares of Robinhoodsurged 50%, continuing a volatile jump after last week's soft initial public offering. Semiconductor stocks were another bright spot, withNvidiaandAdvanced Micro Devicesrising.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks open slightly higher after fall in jobless claims</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks open slightly higher after fall in jobless claims\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-05 21:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(Aug 5)&nbsp;Stocks open slightly higher after fall in jobless claims.</p>\n<p>Dow industrials up 94 points, or 0.3%.&nbsp;S&amp;P 500 up 0.3% at 4,414.12.&nbsp;Nasdaq Composite up less than 0.1% at 14,784.61.&nbsp;</p>\n<p>Fastly plunges over&nbsp;23% in morning trading&nbsp;after the company's downside Q3 and full-year guidance due to the widespread outage in June.</p>\n<p><img src=\"https://static.tigerbbs.com/44fbcf9492918a352919cdff1fd27498\" tg-width=\"727\" tg-height=\"497\" width=\"100%\" height=\"auto\"></p>\n<p>The moves in the stocks came after a mostly lower regular session on Wednesday. The Dow dropped more than 300 points, or 0.9%, and closed near its session low. The S&amp;P 500 slipped about 0.5%, while the Nasdaq Composite ticked up 0.1%.</p>\n<p>Weekly initial jobless claims came in at385,000 on Thursday,in-line with expectations. Recent earnings and economic data have been strong overall, but some economists worry economic growth and employment gains will taper from here.</p>\n<p>The jobless claims data was the last reading before the key July jobs report, which will be released on Friday morning. There is a wide range of estimates from economists and what the report will show, and some metrics for employment gains have disappointed despite a high level of reported job openings.</p>\n<p>\"Many factors are likely driving worker shortages; concerns about catching the virus, childcare responsibilities, skills mismatches, and generous unemployment insurance benefits,\" PNC Senior Economist Abbey Omodunbi said in an email. In the second half of the year, \"more competition for workers, particularly in the leisure and hospitality sector, will support acceleration in wage growth, boosting household incomes and consumer spending.\"</p>\n<p>The results of an ADP private payroll survey released Wednesday showed again of 330,000 jobs for July,well short of the consensus estimate of 653,000. The Labor Department's official jobs report, which typically has more impact on investors, will be released on Friday. Economists expect the report will show the U.S. added 845,000 in non-farm payrolls in July, about even with the previous month, according to Dow Jones estimates.</p>\n<p>The10-year Treasury yieldwas holding steady near 1.8% on Thursday. The yield briefly dipping below 1.13% on Wednesday before bouncing back in late morning trading.</p>\n<p>Shares ofRokudropped 6% after the company issued quarterly results.Etsyfell 12% in early trading after the company gave guidance for the current quarter that indicated the pandemic-fueled commerce boommay be coming to an end.</p>\n<p>However, earnings season has been strong overall. Goldman Sachs raised its year-end target for the S&amp;P 500 to 4,700, representing 7% upside, in part due to an improving earnings outlook going.</p>\n<p>During regular trading Wednesday, shares of Robinhoodsurged 50%, continuing a volatile jump after last week's soft initial public offering. Semiconductor stocks were another bright spot, withNvidiaandAdvanced Micro Devicesrising.</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite","SPY":"标普500ETF",".SPX":"S&P 500 Index"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102705333","content_text":"(Aug 5) Stocks open slightly higher after fall in jobless claims.\nDow industrials up 94 points, or 0.3%. S&P 500 up 0.3% at 4,414.12. Nasdaq Composite up less than 0.1% at 14,784.61. \nFastly plunges over 23% in morning trading after the company's downside Q3 and full-year guidance due to the widespread outage in June.\n\nThe moves in the stocks came after a mostly lower regular session on Wednesday. The Dow dropped more than 300 points, or 0.9%, and closed near its session low. The S&P 500 slipped about 0.5%, while the Nasdaq Composite ticked up 0.1%.\nWeekly initial jobless claims came in at385,000 on Thursday,in-line with expectations. Recent earnings and economic data have been strong overall, but some economists worry economic growth and employment gains will taper from here.\nThe jobless claims data was the last reading before the key July jobs report, which will be released on Friday morning. There is a wide range of estimates from economists and what the report will show, and some metrics for employment gains have disappointed despite a high level of reported job openings.\n\"Many factors are likely driving worker shortages; concerns about catching the virus, childcare responsibilities, skills mismatches, and generous unemployment insurance benefits,\" PNC Senior Economist Abbey Omodunbi said in an email. In the second half of the year, \"more competition for workers, particularly in the leisure and hospitality sector, will support acceleration in wage growth, boosting household incomes and consumer spending.\"\nThe results of an ADP private payroll survey released Wednesday showed again of 330,000 jobs for July,well short of the consensus estimate of 653,000. The Labor Department's official jobs report, which typically has more impact on investors, will be released on Friday. Economists expect the report will show the U.S. added 845,000 in non-farm payrolls in July, about even with the previous month, according to Dow Jones estimates.\nThe10-year Treasury yieldwas holding steady near 1.8% on Thursday. The yield briefly dipping below 1.13% on Wednesday before bouncing back in late morning trading.\nShares ofRokudropped 6% after the company issued quarterly results.Etsyfell 12% in early trading after the company gave guidance for the current quarter that indicated the pandemic-fueled commerce boommay be coming to an end.\nHowever, earnings season has been strong overall. Goldman Sachs raised its year-end target for the S&P 500 to 4,700, representing 7% upside, in part due to an improving earnings outlook going.\nDuring regular trading Wednesday, shares of Robinhoodsurged 50%, continuing a volatile jump after last week's soft initial public offering. Semiconductor stocks were another bright spot, withNvidiaandAdvanced Micro Devicesrising.","news_type":1},"isVote":1,"tweetType":1,"viewCount":137,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":837270728,"gmtCreate":1629897397664,"gmtModify":1676530165389,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/837270728","repostId":"1153815600","repostType":4,"isVote":1,"tweetType":1,"viewCount":460,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":898522502,"gmtCreate":1628512921606,"gmtModify":1703507316736,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/898522502","repostId":"2158844506","repostType":4,"repost":{"id":"2158844506","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1628508062,"share":"https://ttm.financial/m/news/2158844506?lang=&edition=fundamental","pubTime":"2021-08-09 19:21","market":"us","language":"en","title":"BioNTech says has supplied more than 1 bln COVID-19 vaccine doses so far","url":"https://stock-news.laohu8.com/highlight/detail?id=2158844506","media":"Reuters","summary":"FRANKFURT, Aug 9 (Reuters) - BioNTech and partner Pfizer have supplied more than one billion doses o","content":"<p>FRANKFURT, Aug 9 (Reuters) - BioNTech and partner Pfizer have supplied more than <a href=\"https://laohu8.com/S/AONE.U\">one</a> billion doses of their COVID-19 vaccine as per July 21, a bigger number than delivered by competitor AstraZeneca , the German biotech group said on Monday.</p>\n<p>AstraZeneca said on July 29 that it and its manufacturing partner, India-based Serum Institute, had supplied a billion doses to 170 countries at the time.</p>\n<p>Based on delivery contracts so far, BioNTech said in a statement it expects 15.9 billion euros ($18.7 billion) in revenue accruing to it from the vaccine this year, up from a forecast in May of 12.4 billion euros.</p>\n<p>That includes sales, milestone payments from partners and a share of gross profit in its partners' territories, the company added. ($1 = 0.8509 euros)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech says has supplied more than 1 bln COVID-19 vaccine doses so far</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech says has supplied more than 1 bln COVID-19 vaccine doses so far\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-09 19:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>FRANKFURT, Aug 9 (Reuters) - BioNTech and partner Pfizer have supplied more than <a href=\"https://laohu8.com/S/AONE.U\">one</a> billion doses of their COVID-19 vaccine as per July 21, a bigger number than delivered by competitor AstraZeneca , the German biotech group said on Monday.</p>\n<p>AstraZeneca said on July 29 that it and its manufacturing partner, India-based Serum Institute, had supplied a billion doses to 170 countries at the time.</p>\n<p>Based on delivery contracts so far, BioNTech said in a statement it expects 15.9 billion euros ($18.7 billion) in revenue accruing to it from the vaccine this year, up from a forecast in May of 12.4 billion euros.</p>\n<p>That includes sales, milestone payments from partners and a share of gross profit in its partners' territories, the company added. ($1 = 0.8509 euros)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158844506","content_text":"FRANKFURT, Aug 9 (Reuters) - BioNTech and partner Pfizer have supplied more than one billion doses of their COVID-19 vaccine as per July 21, a bigger number than delivered by competitor AstraZeneca , the German biotech group said on Monday.\nAstraZeneca said on July 29 that it and its manufacturing partner, India-based Serum Institute, had supplied a billion doses to 170 countries at the time.\nBased on delivery contracts so far, BioNTech said in a statement it expects 15.9 billion euros ($18.7 billion) in revenue accruing to it from the vaccine this year, up from a forecast in May of 12.4 billion euros.\nThat includes sales, milestone payments from partners and a share of gross profit in its partners' territories, the company added. ($1 = 0.8509 euros)","news_type":1},"isVote":1,"tweetType":1,"viewCount":243,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":801585806,"gmtCreate":1627523138705,"gmtModify":1703491605077,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Ni e","listText":"Ni e","text":"Ni e","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/801585806","repostId":"2155027927","repostType":4,"isVote":1,"tweetType":1,"viewCount":235,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":830326997,"gmtCreate":1629015248819,"gmtModify":1676529911322,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/830326997","repostId":"2159215676","repostType":4,"isVote":1,"tweetType":1,"viewCount":754,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":896420564,"gmtCreate":1628602326258,"gmtModify":1676529793082,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/896420564","repostId":"2158048475","repostType":4,"repost":{"id":"2158048475","kind":"highlight","pubTimestamp":1628600160,"share":"https://ttm.financial/m/news/2158048475?lang=&edition=fundamental","pubTime":"2021-08-10 20:56","market":"us","language":"en","title":"Here's Who's Making a $1 Billion Bet on Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2158048475","media":"Motley Fool","summary":"The total bet size is even higher.","content":"<p>Few stocks are as hot as&nbsp;<b>Moderna</b> (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.</p>\n<p>That kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.</p>\n<p>There's <a href=\"https://laohu8.com/S/AONE.U\">one</a> investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.</p>\n<h2>Investing heavily</h2>\n<p>Moderna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.</p>\n<p>Actually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&amp;D investments going forward.</p>\n<p>In addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.</p>\n<h2>Why buy back shares?</h2>\n<p>Probably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"</p>\n<p>Another reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.</p>\n<p>Moderna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.</p>\n<p>Repurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&amp;D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.</p>\n<p>Moderna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.</p>\n<h2>A good bet?</h2>\n<p>Just because Moderna <i>can</i> spend $1 billion on share repurchases doesn't mean that it <i>should</i> do so. I don't think Moderna should make that $1 billion bet in buying back shares.&nbsp;My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.</p>\n<p>Of course, Moderna could wait to buy back shares only on pullbacks.&nbsp;However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.</p>\n<p>The company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Who's Making a $1 Billion Bet on Moderna</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Who's Making a $1 Billion Bet on Moderna\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 20:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/08/10/heres-whos-making-a-1-billion-bet-on-moderna/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158048475","content_text":"Few stocks are as hot as Moderna (NASDAQ:MRNA) is right now. The vaccine maker's shares have soared more than 360% so far this year. And that comes on top of the 434% gain in 2020.\nThat kind of performance tends to attract investors' attention -- and deservedly so. Some might view the vaccine stock as overpriced now that its market cap tops $190 billion. But not everyone.\nThere's one investor preparing to make a $1 billion bet on Moderna. Who is it? None other than Moderna itself.\nInvesting heavily\nModerna stated in its second-quarter update that its board of directors authorized a share repurchase program of up to $1 billion. Don't expect the company to spend all that money at one time, though. The authorized funds can be used over a two-year period to buy back shares.\nActually, Moderna has invested and will invest a lot more than just $1 billion in its business. CFO David Meline noted in the company's Q2 conference call that Moderna more than tripled its research and development spending year over year in the first half of 2021. He said to expect significantly increased R&D investments going forward.\nIn addition, Moderna plans to make between $450 million and $550 million this year in capital investments. These investments include a major expansion of capacity to be able to manufacture up to 3 billion doses of its COVID-19 vaccine in 2022. The company is also investing in technology improvements and beefing up its global commercial operations.\nWhy buy back shares?\nProbably the most important reason why Moderna is preparing to invest so much in itself is that the company's management team is very confident in its business prospects. CEO Stéphane Bancel said in the Q2 call, \"We are very optimistic about the future of Moderna and we are just getting started.\"\nAnother reason why Moderna is ready to spend up to $1 billion in stock buybacks is that it's likely going to have more cash than it knows what to do with. The company ended the second quarter with a cash stockpile of $12.2 billion. That amount will almost certainly continue to grow.\nModerna expects to rake in $20 billion in sales from its COVID-19 vaccine this year. It already has advance purchase agreements worth $12 billion plus another $8 billion in options for next year.\nRepurchasing shares is actually Moderna's third investment priority. The company first wants to reinvest in its base business, which includes the aforementioned increased R&D and capital spending. Moderna also is interested in expanding its pipeline through business development, deals including licensing and acquisitions.\nModerna's board seems to think that the company will still have plenty of money left over after investing in those two top priorities. Based on the company's revenue projections, it should easily be able to spare $1 billion for stock buybacks.\nA good bet?\nJust because Moderna can spend $1 billion on share repurchases doesn't mean that it should do so. I don't think Moderna should make that $1 billion bet in buying back shares. My view is that stock buybacks at Moderna's current valuation (or anywhere close to it) would be ill-advised.\nOf course, Moderna could wait to buy back shares only on pullbacks. However, unless its shares plunge significantly, I think that Moderna would better serve its shareholders by making a strategic acquisition with the $1 billion than buying its own richly priced shares.\nThe company needs to be able to generate growth after the worst of the pandemic ends. With only one non-COVID-19 pipeline candidate soon to enter late-stage testing, buying a smaller biotech is the easiest way to achieve that growth.","news_type":1},"isVote":1,"tweetType":1,"viewCount":120,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":804038781,"gmtCreate":1627911555543,"gmtModify":1703497711425,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/804038781","repostId":"2156192895","repostType":4,"repost":{"id":"2156192895","kind":"highlight","pubTimestamp":1627909020,"share":"https://ttm.financial/m/news/2156192895?lang=&edition=fundamental","pubTime":"2021-08-02 20:57","market":"us","language":"en","title":"Can Last Year's Biggest Vaccine Stocks Crush the Market Again?","url":"https://stock-news.laohu8.com/highlight/detail?id=2156192895","media":"Motley Fool","summary":"These players delivered triple- and quadruple-digit gains.","content":"<blockquote>\n <b>These players delivered triple- and quadruple-digit gains.</b>\n</blockquote>\n<p><b>Key <a href=\"https://laohu8.com/S/PCOM\">Points</a></b></p>\n<ul>\n <li>Last year, most coronavirus vaccine stocks were high risk.</li>\n <li>Today, there are investment opportunities for aggressive investors and cautious investors.</li>\n</ul>\n<p>Coronavirus vaccine stocks were the biggest investment theme of 2020. Some players soared more than 1,000% as investors bet on their abilities to bring a billion-dollar product to market. That's as the S&amp;P 500 Index rose about 16%.</p>\n<p>Since, two biotech companies --<b>Moderna</b> (NASDAQ:MRNA) and&nbsp;<b><a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a></b> -- actually have commercialized their vaccines. And they are indeed generating billions of dollars in revenue. But what about some of the other vaccine stocks that scored big on the stock market last year? Let's take a look at where they're at with vaccine programs -- and whether they're on track to beat the market in the second half.</p>\n<p><img src=\"https://static.tigerbbs.com/4892523d64861e597e6e75e31fe85713\" tg-width=\"700\" tg-height=\"467\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<p><b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b></p>\n<p>The program:&nbsp;<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>'s U.S. phase 3 trial of its vaccine candidate showed 90.4% overall efficacy. It demonstrated 100% efficacy in moderate and severe disease. The company fell behind in its submissions to regulators as it ramped up its manufacturing network. For instance, it's faced shortages of certain raw materials needed to produce the vaccine candidate. In May, Novavax said it would file for authorization in various locations worldwide -- including the U.S. -- in the third quarter. And Novavax predicts manufacturing will operate at full capacity as of the fourth quarter.</p>\n<p>The share price: The stock rose 90% in the first half. That's after soaring 2,700% last year.</p>\n<p>Are more share gains on the horizon? Novavax said in its latest earnings call that it expects to generate billions of dollars in revenue over the next four to six quarters. If Novavax wins vaccine authorization in the coming months, this could become a reality. The company already has orders to deliver 200 million doses to various countries. All of this could equal solid share performance in the second half.</p>\n<p><img src=\"https://static.tigerbbs.com/54a0fc748f5a7357128a290dd852b959\" tg-width=\"720\" tg-height=\"534\" referrerpolicy=\"no-referrer\"></p>\n<p>NVAX data by YCharts</p>\n<p><b>Vaxart</b></p>\n<p>The program:&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> seemed out of the race earlier in the year. The company's phase 1 trial showed its oral vaccine candidate didn't produce neutralizing antibodies. They are seen as key to preventing infection. But additional trial data demonstrated strength in producing killer T cell responses. This powerful immune system tool is another way to fight infection. Vaxart said it would launch a phase 2 study of its candidate mid-year. It will start a phase 1/2 study of a variant-specific candidate in the third quarter.</p>\n<p>The share price: Vaxart shares climbed 31% in the first half. That follows last year's 1,500% increase.</p>\n<p>Are more share gains on the horizon? Vaxart remains risky. Any negative news in the second half could be disastrous. Still, the idea of a vaccine in pill form could be a game-changer. If the company announces trial starts as planned, the shares may outperform the market in the coming months. And any positive data could offer a major boost.</p>\n<p><b><a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b></p>\n<p>The program: Moderna reported more than $1 billion in profit -- its first profit ever -- after <a href=\"https://laohu8.com/S/AONE.U\">one</a> full quarter of coronavirus vaccine sales. The company expects at least $19.2 billion in vaccine revenue this year. It's already won 2022 orders from countries including the U.S., Israel, and Switzerland. And the company predicts need for the vaccine could be greater next year than this year.</p>\n<p>The share price: Moderna shares rose about 125% in the first half -- and added more than 40% over the past month. That's after a 434% increase last year.</p>\n<p>Are more share gains on the horizon? Moderna is likely to beat the S&amp;P 500 in the second half if three key things happen: The company reports new contracts for 2022, successfully gains authorization for the use of its vaccine in teens, and gets the regulatory nod for a booster. I'm pretty optimistic about each.</p>\n<p><b><a href=\"https://laohu8.com/S/ARCT\">Arcturus Therapeutics Ltd.</a> </b></p>\n<p>The program:<b>Arcturus Therapeutics</b> (NASDAQ:ARCT) is testing its mRNA vaccine in a phase 2 study and plans on reporting data in the second half. The product could stand out from mRNA rivals<b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b> and Moderna because it's freeze-dried and given in <a href=\"https://laohu8.com/S/AONE.U\">one</a> dose. The Pfizer and Moderna vaccines require cold storage and are given in two shots.</p>\n<p>The share price: Arcturus shares slipped 22% in the first half. Last year, they surged 299%.</p>\n<p>Is a share price recovery on the horizon? The above advantages sound great. But here's the problem: In a phase 1 study, Arcturus' candidate produced lower neutralizing antibody levels than the Pfizer and Moderna jabs. This translates into lower efficacy. If the next batch of data shows stronger results, the shares could climb. But if performance remains well below rivals, I wouldn't expect Arcturus to beat the S&amp;P 500 in the second half.</p>\n<p><img src=\"https://static.tigerbbs.com/cd5cf54e35734c9da8a1260f2c3436bc\" tg-width=\"720\" tg-height=\"534\" referrerpolicy=\"no-referrer\"></p>\n<p>NVAX data by YCharts</p>\n<p><b>Ocugen</b></p>\n<p>The program:&nbsp;<b>Ocugen</b> (NASDAQ:OCGN) in December announced it would partner with India's Bharat Biotech to co-commercialize its late-stage coronavirus vaccine in the U.S. More recently, the U.S. Food and Drug Administration advised Ocugen to pursue a traditional regulatory path rather than Emergency Use Authorization (EUA). Ocugen also gained rights to co-commercialize the candidate in Canada and has started a rolling submission there.</p>\n<p>The share price: Ocugen stock soared 338% in the first half. That's after climbing more than 251% last year (with almost all of that gain coming after the Bharat partnership announcement).</p>\n<p>Are more share gains on the horizon? Ocugen remains high risk. <a href=\"https://laohu8.com/S/ISBC\">Investors</a> were betting on big revenue from a possible EUA in the U.S. Now, revenue possibilities seem lower and farther off. The stock may continue to climb in the second half if Canada moves quickly on an authorization. But in my opinion, over the long term, the shares are like a house of cards. If U.S. approval doesn't happen or takes too long, they may collapse.</p>\n<p><b><a href=\"https://laohu8.com/S/INO\">Inovio Pharmaceuticals</a> </b></p>\n<p>The program: Earlier this year, the U.S. government dropped plans to fund<b><a href=\"https://laohu8.com/S/INO\">Inovio Pharmaceuticals</a></b>' (NASDAQ:INO) phase 3 trial. The government cited the rapid launch of other vaccines into the marketplace. As a result, Inovio said it would conduct phase 3 primarily outside of the U.S. The company aims to launch the trial with Chinese partner Advaccine Biopharmaceuticals Suzhou this summer. Inovio also is working on a next-generation \"pan-COVID\" vaccine candidate. It plans to start clinical testing on the candidate this year.</p>\n<p>The share price: Inovio added 4.8% in the first half. That's after climbing 168% last year.</p>\n<p>Are more share gains on the horizon? Inovio is another high-risk stock. Its initial candidate may have trouble carving out share in a market dominated by solid players. Most promising is the pan-COVID candidate. Especially considering the growth of variants. But we'll need clinical trial data to see if the potential product actually works. I would be surprised if Inovio beat the S&amp;P 500 in the second half of this year. The pan-COVID candidate makes Inovio a stock to watch -- but from a distance.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Can Last Year's Biggest Vaccine Stocks Crush the Market Again?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCan Last Year's Biggest Vaccine Stocks Crush the Market Again?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-02 20:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/02/can-these-big-vaccine-stocks-crush-market-again/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These players delivered triple- and quadruple-digit gains.\n\nKey Points\n\nLast year, most coronavirus vaccine stocks were high risk.\nToday, there are investment opportunities for aggressive investors ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/02/can-these-big-vaccine-stocks-crush-market-again/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","VXRT":"Vaxart, Inc","BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","OCGN":"Ocugen","INO":"伊诺维奥制药","NVAX":"诺瓦瓦克斯医药","ARCT":"Arcturus Therapeutics Ltd."},"source_url":"https://www.fool.com/investing/2021/08/02/can-these-big-vaccine-stocks-crush-market-again/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156192895","content_text":"These players delivered triple- and quadruple-digit gains.\n\nKey Points\n\nLast year, most coronavirus vaccine stocks were high risk.\nToday, there are investment opportunities for aggressive investors and cautious investors.\n\nCoronavirus vaccine stocks were the biggest investment theme of 2020. Some players soared more than 1,000% as investors bet on their abilities to bring a billion-dollar product to market. That's as the S&P 500 Index rose about 16%.\nSince, two biotech companies --Moderna (NASDAQ:MRNA) and BioNTech SE -- actually have commercialized their vaccines. And they are indeed generating billions of dollars in revenue. But what about some of the other vaccine stocks that scored big on the stock market last year? Let's take a look at where they're at with vaccine programs -- and whether they're on track to beat the market in the second half.\n\nImage source: Getty Images.\nNovavax\nThe program: Novavax's U.S. phase 3 trial of its vaccine candidate showed 90.4% overall efficacy. It demonstrated 100% efficacy in moderate and severe disease. The company fell behind in its submissions to regulators as it ramped up its manufacturing network. For instance, it's faced shortages of certain raw materials needed to produce the vaccine candidate. In May, Novavax said it would file for authorization in various locations worldwide -- including the U.S. -- in the third quarter. And Novavax predicts manufacturing will operate at full capacity as of the fourth quarter.\nThe share price: The stock rose 90% in the first half. That's after soaring 2,700% last year.\nAre more share gains on the horizon? Novavax said in its latest earnings call that it expects to generate billions of dollars in revenue over the next four to six quarters. If Novavax wins vaccine authorization in the coming months, this could become a reality. The company already has orders to deliver 200 million doses to various countries. All of this could equal solid share performance in the second half.\n\nNVAX data by YCharts\nVaxart\nThe program: Vaxart, Inc seemed out of the race earlier in the year. The company's phase 1 trial showed its oral vaccine candidate didn't produce neutralizing antibodies. They are seen as key to preventing infection. But additional trial data demonstrated strength in producing killer T cell responses. This powerful immune system tool is another way to fight infection. Vaxart said it would launch a phase 2 study of its candidate mid-year. It will start a phase 1/2 study of a variant-specific candidate in the third quarter.\nThe share price: Vaxart shares climbed 31% in the first half. That follows last year's 1,500% increase.\nAre more share gains on the horizon? Vaxart remains risky. Any negative news in the second half could be disastrous. Still, the idea of a vaccine in pill form could be a game-changer. If the company announces trial starts as planned, the shares may outperform the market in the coming months. And any positive data could offer a major boost.\nModerna, Inc.\nThe program: Moderna reported more than $1 billion in profit -- its first profit ever -- after one full quarter of coronavirus vaccine sales. The company expects at least $19.2 billion in vaccine revenue this year. It's already won 2022 orders from countries including the U.S., Israel, and Switzerland. And the company predicts need for the vaccine could be greater next year than this year.\nThe share price: Moderna shares rose about 125% in the first half -- and added more than 40% over the past month. That's after a 434% increase last year.\nAre more share gains on the horizon? Moderna is likely to beat the S&P 500 in the second half if three key things happen: The company reports new contracts for 2022, successfully gains authorization for the use of its vaccine in teens, and gets the regulatory nod for a booster. I'm pretty optimistic about each.\nArcturus Therapeutics Ltd. \nThe program:Arcturus Therapeutics (NASDAQ:ARCT) is testing its mRNA vaccine in a phase 2 study and plans on reporting data in the second half. The product could stand out from mRNA rivalsPfizer and Moderna because it's freeze-dried and given in one dose. The Pfizer and Moderna vaccines require cold storage and are given in two shots.\nThe share price: Arcturus shares slipped 22% in the first half. Last year, they surged 299%.\nIs a share price recovery on the horizon? The above advantages sound great. But here's the problem: In a phase 1 study, Arcturus' candidate produced lower neutralizing antibody levels than the Pfizer and Moderna jabs. This translates into lower efficacy. If the next batch of data shows stronger results, the shares could climb. But if performance remains well below rivals, I wouldn't expect Arcturus to beat the S&P 500 in the second half.\n\nNVAX data by YCharts\nOcugen\nThe program: Ocugen (NASDAQ:OCGN) in December announced it would partner with India's Bharat Biotech to co-commercialize its late-stage coronavirus vaccine in the U.S. More recently, the U.S. Food and Drug Administration advised Ocugen to pursue a traditional regulatory path rather than Emergency Use Authorization (EUA). Ocugen also gained rights to co-commercialize the candidate in Canada and has started a rolling submission there.\nThe share price: Ocugen stock soared 338% in the first half. That's after climbing more than 251% last year (with almost all of that gain coming after the Bharat partnership announcement).\nAre more share gains on the horizon? Ocugen remains high risk. Investors were betting on big revenue from a possible EUA in the U.S. Now, revenue possibilities seem lower and farther off. The stock may continue to climb in the second half if Canada moves quickly on an authorization. But in my opinion, over the long term, the shares are like a house of cards. If U.S. approval doesn't happen or takes too long, they may collapse.\nInovio Pharmaceuticals \nThe program: Earlier this year, the U.S. government dropped plans to fundInovio Pharmaceuticals' (NASDAQ:INO) phase 3 trial. The government cited the rapid launch of other vaccines into the marketplace. As a result, Inovio said it would conduct phase 3 primarily outside of the U.S. The company aims to launch the trial with Chinese partner Advaccine Biopharmaceuticals Suzhou this summer. Inovio also is working on a next-generation \"pan-COVID\" vaccine candidate. It plans to start clinical testing on the candidate this year.\nThe share price: Inovio added 4.8% in the first half. That's after climbing 168% last year.\nAre more share gains on the horizon? Inovio is another high-risk stock. Its initial candidate may have trouble carving out share in a market dominated by solid players. Most promising is the pan-COVID candidate. Especially considering the growth of variants. But we'll need clinical trial data to see if the potential product actually works. I would be surprised if Inovio beat the S&P 500 in the second half of this year. The pan-COVID candidate makes Inovio a stock to watch -- but from a distance.","news_type":1},"isVote":1,"tweetType":1,"viewCount":158,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":834243983,"gmtCreate":1629809891742,"gmtModify":1676530138006,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/834243983","repostId":"1192610173","repostType":4,"repost":{"id":"1192610173","kind":"news","pubTimestamp":1629809650,"share":"https://ttm.financial/m/news/1192610173?lang=&edition=fundamental","pubTime":"2021-08-24 20:54","market":"us","language":"en","title":"What Jackson Hole Could Mean For Apple Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1192610173","media":"TheStreet","summary":"In late August, the markets could be rocked by monetary policy news coming from Jackson Hole, Wyomin","content":"<p>In late August, the markets could be rocked by monetary policy news coming from Jackson Hole, Wyoming. Here is what Apple stock investors should expect.</p>\n<p>The week of August 23 will likely prove to be an important one in the markets. Starting on Thursday, central bank leaders from around the world will meet virtually to talk about monetary policy during a traditional&nbsp;event&nbsp;often referred to simply as “Jackson Hole”.</p>\n<p>Today, the Apple Maven discusses how the upcoming meeting of central bankers could impact Apple stock’s&nbsp;performance in the last few trading sessions of August.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb09ec199963ac68c7742982748bf7a0\" tg-width=\"1200\" tg-height=\"800\" width=\"100%\" height=\"auto\"><span>Figure 1: Federal Reserve Chair Jerome Powell in a screen display at NYSE.</span></p>\n<p><b>The interest rate risk</b></p>\n<p>There seems to be a consensus that Federal Reserve chairman Jerome Powell will do little to “rock the boat” this week. Easing off on monetary stimulus is widely expected to occur over the next several months, but few seem confident that Mr. Powell will announce a change in policy as early as August.</p>\n<p>Still, the risk that the Fed will start to scale back its asset purchases later this year is real. Analysts will probably dissect Jerome Powell’s keynote speech, on Friday, in search for clues on the exact timing. Comments perceived to be hawkish could send yields higher – the 10-year treasury rate is only 1.3%.</p>\n<p>If recent history can serve as a guide,climbing yields tend to be bad news&nbsp;for growth stocks. Below are the main reasons why this is the case, as previously discussed on this channel:</p>\n<blockquote>\n “First, monetary tightening is a negative for consumption, everything else held constant. Second, a higher discount rate makes Apple’s far-out financial results less valuable in present value terms.”\n</blockquote>\n<p>For instance, the 10-year rate shot up from around 1% to nearly 1.5% in February alone. Probably not a coincidence, AAPL sank 8% that same month, while the value-rich Dow index managed to reach higher.</p>\n<p><b>Brace for possible volatility</b></p>\n<p>Regardless of which way the stock market may head following the Jackson Hole symposium, volatility could rise as August comes to a close. This is the case because speculation, both on the bullish and bearish sides of the argument, tends to increase around important events like this.</p>\n<p>Volatility is both good and bad news for Apple stock. Market jitters can be uncomfortable for many investors, and some might be tempted to sell or trim their positions after a selloff. On the other hand, a possible pullback that is unrelated to the company’s fundamentals could open an opportunity to buy AAPL on weakness.</p>\n<p>This is precisely what happened in mid-June, following an important Federal Reserve meeting that the market perceived as hawkish. Those&nbsp;who bought AAPL at those levels, a move defended by the Apple Maven, saw the value of their investment rise by 14% in a matter of only about 10 weeks.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What Jackson Hole Could Mean For Apple Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat Jackson Hole Could Mean For Apple Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-24 20:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/apple/news/what-jackson-hole-could-mean-for-apple-stock><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In late August, the markets could be rocked by monetary policy news coming from Jackson Hole, Wyoming. Here is what Apple stock investors should expect.\nThe week of August 23 will likely prove to be ...</p>\n\n<a href=\"https://www.thestreet.com/apple/news/what-jackson-hole-could-mean-for-apple-stock\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.thestreet.com/apple/news/what-jackson-hole-could-mean-for-apple-stock","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192610173","content_text":"In late August, the markets could be rocked by monetary policy news coming from Jackson Hole, Wyoming. Here is what Apple stock investors should expect.\nThe week of August 23 will likely prove to be an important one in the markets. Starting on Thursday, central bank leaders from around the world will meet virtually to talk about monetary policy during a traditional event often referred to simply as “Jackson Hole”.\nToday, the Apple Maven discusses how the upcoming meeting of central bankers could impact Apple stock’s performance in the last few trading sessions of August.\nFigure 1: Federal Reserve Chair Jerome Powell in a screen display at NYSE.\nThe interest rate risk\nThere seems to be a consensus that Federal Reserve chairman Jerome Powell will do little to “rock the boat” this week. Easing off on monetary stimulus is widely expected to occur over the next several months, but few seem confident that Mr. Powell will announce a change in policy as early as August.\nStill, the risk that the Fed will start to scale back its asset purchases later this year is real. Analysts will probably dissect Jerome Powell’s keynote speech, on Friday, in search for clues on the exact timing. Comments perceived to be hawkish could send yields higher – the 10-year treasury rate is only 1.3%.\nIf recent history can serve as a guide,climbing yields tend to be bad news for growth stocks. Below are the main reasons why this is the case, as previously discussed on this channel:\n\n “First, monetary tightening is a negative for consumption, everything else held constant. Second, a higher discount rate makes Apple’s far-out financial results less valuable in present value terms.”\n\nFor instance, the 10-year rate shot up from around 1% to nearly 1.5% in February alone. Probably not a coincidence, AAPL sank 8% that same month, while the value-rich Dow index managed to reach higher.\nBrace for possible volatility\nRegardless of which way the stock market may head following the Jackson Hole symposium, volatility could rise as August comes to a close. This is the case because speculation, both on the bullish and bearish sides of the argument, tends to increase around important events like this.\nVolatility is both good and bad news for Apple stock. Market jitters can be uncomfortable for many investors, and some might be tempted to sell or trim their positions after a selloff. On the other hand, a possible pullback that is unrelated to the company’s fundamentals could open an opportunity to buy AAPL on weakness.\nThis is precisely what happened in mid-June, following an important Federal Reserve meeting that the market perceived as hawkish. Those who bought AAPL at those levels, a move defended by the Apple Maven, saw the value of their investment rise by 14% in a matter of only about 10 weeks.","news_type":1},"isVote":1,"tweetType":1,"viewCount":143,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":890361126,"gmtCreate":1628084077765,"gmtModify":1703500886221,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/890361126","repostId":"2156909108","repostType":4,"isVote":1,"tweetType":1,"viewCount":150,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":801584980,"gmtCreate":1627523156340,"gmtModify":1703491606207,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/801584980","repostId":"1189200524","repostType":4,"isVote":1,"tweetType":1,"viewCount":93,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":809845655,"gmtCreate":1627361040877,"gmtModify":1703488378395,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Wiw","listText":"Wiw","text":"Wiw","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/809845655","repostId":"1162276557","repostType":4,"isVote":1,"tweetType":1,"viewCount":147,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":175434967,"gmtCreate":1627045865659,"gmtModify":1703483162753,"author":{"id":"3581492791156392","authorId":"3581492791156392","name":"FantasyX","avatar":"https://static.tigerbbs.com/d5be60dde27e883d6f8b569b3afe2f3f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581492791156392","authorIdStr":"3581492791156392"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/175434967","repostId":"2153983451","repostType":4,"repost":{"id":"2153983451","kind":"highlight","pubTimestamp":1627045260,"share":"https://ttm.financial/m/news/2153983451?lang=&edition=fundamental","pubTime":"2021-07-23 21:01","market":"us","language":"en","title":"Is It Too Late to Buy Moderna Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2153983451","media":"Motley Fool","summary":"Past performance isn't necessarily indicative of future success -- but in this case it might just be.","content":"<p>If you had invested $100,000 in <b><a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b> in early 2020, you would have well over $1,500,000 today, as shares of the biotech have skyrocketed thanks to its successful development of a vaccine for COVID-19. Any investor would be proud of such returns, particularly given the relatively short period it took the vaccine maker to accomplish this feat.</p>\n<p>But that raises an interesting question: After crushing the broader market over the past year and a half, how much upside does Moderna have left? Is it too late to get in on this high-flying biotech? Let's look into Moderna's prospects, both within the coronavirus market and beyond, to determine whether it is still worth purchasing its shares.</p>\n<p><img src=\"https://static.tigerbbs.com/c956dab14bf4026173f313850104ad4c\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"></p>\n<p>^SPX data by YCharts</p>\n<h3>Is the coronavirus vaccine tailwind over?</h3>\n<p>According to the U.S. Centers for Disease Control and Prevention (CDC), as of July 21, 161.9 million people in the U.S. have been fully vaccinated against COVID-19. Many more have received vaccines elsewhere in the world. The two leaders in this space -- Moderna and <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b> -- have both reported that their respective vaccines are still effective after six months.</p>\n<p>There is evidence that Moderna's vaccine, mRNA-1273, is also potent against newer variants of the SARS-CoV-2 virus that causes the disease, including the delta variant that is now responsible for over 80% of new cases in the U.S. One could conclude from these facts that Moderna won't benefit a whole lot more from mRNA-1273.&nbsp;After all, the company's shares have already skyrocketed, and with the number of vaccinated people rising, how much can the biotech continue to profit from its success in this market?</p>\n<p>However, there are good reasons to think Moderna's coronavirus vaccine-related tailwind isn't over. <a href=\"https://laohu8.com/S/FBNC\">First</a>, Moderna continues to seek (and earn) regulatory wins, both in the U.S. and abroad. Back in June, the company applied for an Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for its vaccine to be administered to adolescents between the ages of 12 and 18. Moderna submitted a similar application to regulatory authorities in Switzerland last month, and the company's vaccine recently earned an EUA in India.</p>\n<p><img src=\"https://static.tigerbbs.com/6745743754cc8a567a6c76661e415ed8\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<p>Second, the biotech continues to sign new supply deals for mRNA-1273. Moderna announced a supply agreement with the government of Argentina on June 12 for 20 million doses of mRNA-1273, while both the U.S. government and the European Commission have purchased millions of additional doses of the vaccine.</p>\n<p>Finally, and perhaps most importantly, it still isn't clear how long mRNA-1273 provides immunity. During Moderna's first-quarter earnings conference call, CEO Stéphane Bancel said: \"we believe booster shots will be needed as we believe that the virus is not going away. We also believe from the scientific standpoint, that the highest efficacy booster over time will be provided by multivalent variant-specific booster.\"</p>\n<p>Moderna started evaluating booster candidates for its vaccine earlier this year.&nbsp;Meanwhile, Pfizer's CEO Albert Bourla has said that he believes demand for COVID-19 vaccines could become seasonal, much like the demand for flu vaccines.&nbsp;Of course, none of this is set in stone. The CDC and the FDA released a joint statement on July 8 saying that vaccinated Americans do not need booster shots right now.</p>\n<p>That may be true at the moment, but data from Pfizer has already strongly suggested that a booster dose administered six months post-vaccination produces higher antibodies titers in patients. This is important -- while Pfizer's vaccine remains effective after six months, its efficacy does seem to decrease.</p>\n<p>And with new variants like delta emerging, there are good reasons to think that a booster dose will eventually be needed for vaccinated people. Given these factors, it seems highly likely that Moderna will continue to benefit from its coronavirus vaccine financially, and its shares could still experience significant upside as a result.</p>\n<h3>What else does Moderna have to offer?</h3>\n<p>Beyond COVID-19, Moderna's mRNA vaccine platform shows huge potential. The company's pipeline currently boasts more than a dozen programs, most of which are potential vaccines against various infectious illnesses.&nbsp;In early July, the biotech started a phase 1/2 clinical trial for mRNA-1010, an investigational flu vaccine.</p>\n<p>The company argues that despite the wide availability of approved vaccines for the flu, this disease continues to cause serious health problems, in part because current vaccines are only 40% to 60% effective. Moderna is also looking to develop combination vaccines -- that is, vaccines that can confer immunity against more than <a href=\"https://laohu8.com/S/AONE.U\">one</a> disease.</p>\n<p>There is no doubt the long-term opportunity is there for the company. As Moderna argues, of the more than 80 viruses discovered in the past 40 years, only 4% have commercially available vaccines in the U.S. The company thinks its mRNA approach to vaccination could help it create a raft of effective vaccines against some of these viruses.</p>\n<h3>Not too late to get in</h3>\n<p>There are two important reasons why it's not too late to buy shares of Moderna. <a href=\"https://laohu8.com/S/FFBC\">First</a>, the company will continue to benefit from its COVID-19 vaccine. Second, the biotech's long-term thesis (supported by the success of mRNA-1273) is attractive. Moderna is currently trading at just 12.5 times forward earnings, which, in my view, is more than fair given the company's prospects. <a href=\"https://laohu8.com/S/ISBC\">Investors</a> looking for solid biotech stocks to buy need look no further than Moderna.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Too Late to Buy Moderna Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Too Late to Buy Moderna Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-23 21:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/23/is-it-too-late-to-buy-moderna-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you had invested $100,000 in Moderna, Inc. in early 2020, you would have well over $1,500,000 today, as shares of the biotech have skyrocketed thanks to its successful development of a vaccine for ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/23/is-it-too-late-to-buy-moderna-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/07/23/is-it-too-late-to-buy-moderna-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153983451","content_text":"If you had invested $100,000 in Moderna, Inc. in early 2020, you would have well over $1,500,000 today, as shares of the biotech have skyrocketed thanks to its successful development of a vaccine for COVID-19. Any investor would be proud of such returns, particularly given the relatively short period it took the vaccine maker to accomplish this feat.\nBut that raises an interesting question: After crushing the broader market over the past year and a half, how much upside does Moderna have left? Is it too late to get in on this high-flying biotech? Let's look into Moderna's prospects, both within the coronavirus market and beyond, to determine whether it is still worth purchasing its shares.\n\n^SPX data by YCharts\nIs the coronavirus vaccine tailwind over?\nAccording to the U.S. Centers for Disease Control and Prevention (CDC), as of July 21, 161.9 million people in the U.S. have been fully vaccinated against COVID-19. Many more have received vaccines elsewhere in the world. The two leaders in this space -- Moderna and Pfizer -- have both reported that their respective vaccines are still effective after six months.\nThere is evidence that Moderna's vaccine, mRNA-1273, is also potent against newer variants of the SARS-CoV-2 virus that causes the disease, including the delta variant that is now responsible for over 80% of new cases in the U.S. One could conclude from these facts that Moderna won't benefit a whole lot more from mRNA-1273. After all, the company's shares have already skyrocketed, and with the number of vaccinated people rising, how much can the biotech continue to profit from its success in this market?\nHowever, there are good reasons to think Moderna's coronavirus vaccine-related tailwind isn't over. First, Moderna continues to seek (and earn) regulatory wins, both in the U.S. and abroad. Back in June, the company applied for an Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for its vaccine to be administered to adolescents between the ages of 12 and 18. Moderna submitted a similar application to regulatory authorities in Switzerland last month, and the company's vaccine recently earned an EUA in India.\n\nImage source: Getty Images.\nSecond, the biotech continues to sign new supply deals for mRNA-1273. Moderna announced a supply agreement with the government of Argentina on June 12 for 20 million doses of mRNA-1273, while both the U.S. government and the European Commission have purchased millions of additional doses of the vaccine.\nFinally, and perhaps most importantly, it still isn't clear how long mRNA-1273 provides immunity. During Moderna's first-quarter earnings conference call, CEO Stéphane Bancel said: \"we believe booster shots will be needed as we believe that the virus is not going away. We also believe from the scientific standpoint, that the highest efficacy booster over time will be provided by multivalent variant-specific booster.\"\nModerna started evaluating booster candidates for its vaccine earlier this year. Meanwhile, Pfizer's CEO Albert Bourla has said that he believes demand for COVID-19 vaccines could become seasonal, much like the demand for flu vaccines. Of course, none of this is set in stone. The CDC and the FDA released a joint statement on July 8 saying that vaccinated Americans do not need booster shots right now.\nThat may be true at the moment, but data from Pfizer has already strongly suggested that a booster dose administered six months post-vaccination produces higher antibodies titers in patients. This is important -- while Pfizer's vaccine remains effective after six months, its efficacy does seem to decrease.\nAnd with new variants like delta emerging, there are good reasons to think that a booster dose will eventually be needed for vaccinated people. Given these factors, it seems highly likely that Moderna will continue to benefit from its coronavirus vaccine financially, and its shares could still experience significant upside as a result.\nWhat else does Moderna have to offer?\nBeyond COVID-19, Moderna's mRNA vaccine platform shows huge potential. The company's pipeline currently boasts more than a dozen programs, most of which are potential vaccines against various infectious illnesses. In early July, the biotech started a phase 1/2 clinical trial for mRNA-1010, an investigational flu vaccine.\nThe company argues that despite the wide availability of approved vaccines for the flu, this disease continues to cause serious health problems, in part because current vaccines are only 40% to 60% effective. Moderna is also looking to develop combination vaccines -- that is, vaccines that can confer immunity against more than one disease.\nThere is no doubt the long-term opportunity is there for the company. As Moderna argues, of the more than 80 viruses discovered in the past 40 years, only 4% have commercially available vaccines in the U.S. The company thinks its mRNA approach to vaccination could help it create a raft of effective vaccines against some of these viruses.\nNot too late to get in\nThere are two important reasons why it's not too late to buy shares of Moderna. First, the company will continue to benefit from its COVID-19 vaccine. Second, the biotech's long-term thesis (supported by the success of mRNA-1273) is attractive. Moderna is currently trading at just 12.5 times forward earnings, which, in my view, is more than fair given the company's prospects. Investors looking for solid biotech stocks to buy need look no further than Moderna.","news_type":1},"isVote":1,"tweetType":1,"viewCount":238,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}